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ABSTRACT 
Fluoroquinolone susceptible and resistant Campylobacter coli were isolated from pigs 
on two separate pig farms. C. coli are enteric pathogens of humans and animals and 
although diarrhoea resulting from C. coli and C. jejuni is generally a self-limiting 
disease, in severe cases, fluoroquinolones are the choice antibiotic for treatment. The 
presence of fluoroquinolone resistant C. coli strains in the food chain is cause for 
concern as this may be a source of resistant strains in humans. 
Sixty-one isolates were included in the study: 26 were susceptible to nalidixic acid 
and ciprofloxacin and 35 were resistant to these antibiotics. Fifty-five strains were 
obtained from pigs on farm A, while 6 strains were obtained from pigs on farm B, the 
source farm of pigs to farm A. Serotyping and flaA typing were carried out to study 
the epidemiology of the isolates. Serotyping identified 0:24 (11/61) as the most 
frequent serotype isolated, followed by 0:5 (7/61). Common serotypes 0:48, 0:54 
and 0:59 were identified in strains from both farms. A high number of the strains 
were non-typeable (23/61) but were distinguished by flaA typing. RFLP analysis of 
the flaA gene revealed 13 distinct profiles in strains from farm A, and 4 profiles in 
strains from farm B, of which only 1 was unique to farm B. Profile 1 was the 
commonest profile observed with 31 % (17 /55) of flaA typed strains in this profile. 
There was an association between 0:24, profile 6, and resistance. Resistant and 
sensitive pairs were isolated from 15 pigs; flaA profiles of each of 4 pairs were 
identical, suggesting selection of resistant mutants from previously sensitive 
populations. 
An investigation of the molecular basis of the fluoroquinolone resistance identified a 
Thr-86 to Ile mutation in GyrA, the primary target of these antibiotics. 
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1.1 THE GENUS CAMPYLOBACTER 
The genus Campylobacter comprises a group of closely related curved or spiral, 
gram-negative bacteria that primarily colonise the gastrointestinal tracts of a variety of 
different host species (On, 1996). Campylobacter are non-spore forming rods, 
varying in length from 0.5 µm to 6.0 µm and a width of 0.2 µm to 0.5 µm. They are 
motile flagellate bacteria, possessing a single polar unsheathed flagellum at one or 
both ends (Fig 1.1 ), with a characteristic corkscrew-like, darting motion (Rollins & 
Colwell, 1986; Vandamme et al., 1991). Cells of some species are nonmotile 
(Campylobacter gracilis) or have multiple flagella (Campylobacter showae). 
Figure 1.1. An electron micrograph of Campylobacter. Original magnification, x30,000. 
Kindly provided by Dr. L Stannard. 
Campylobacter are micro-aerophilic and are damaged by normal atmospheric levels 
of 0 2 (20%) and require 0 2 levels below the range of 2-10%. Growth is achieved 
optimally at a temperature range of 30-42°C and high concentrations of carbon 
dioxide and hydrogen. These microorganisms are acid sensitive and do not grow 
below a pH of 4.9 making them fastidious and relatively slow growers. 
Campylobacter have a low G+C content ranging from 30-38% (Prescott et al., 1996). 
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1.1.1 Taxonomy 
The taxonomic classification of the genus Campylobacter has constantly evolved and 
has been extensively revised over the last century, particularly in the last 2 decades. 
Originally, the genus contained only two taxa, Campylobacter fetus and C. bubulus 
(Vandamme & Goosens, 1992; On, 1996). John McFadyean was the first to isolate 
campylobacters in pure culture from an aborted sheep foetus (McFadyean & 
Stockman, 1913). The "vibrio" like bacteria was called Vibrio fetus. In 1963, the 
genus Campylobacter was proposed to accommodate what had until then been 
regarded as microaerophilic vibrios and Vibrio fetus was changed to Campylobacter 
fetus (Vandamme & Goosens, 1992; Skirrow, 1994). 
Since 1988, a new Campylobacter species has been identified every year. Currently 
15 Campylobacter species and six subsp. are recognised. The main species making up 
the genus Campylobacter are: C. fetus , C. hyointestinalis, C. concisus, C. mucosa/is, 
C. sputorum, C. curvus, C. rectus, C. showae, C. gracilis, C. upsaliensis, C. 
helveticus, C. hyoilei, C. lari, C. jejuni and C. coli. Most c.ampylobacters and 
Campylobacter-like organisms have been assigned to rRNA superfamily VI that 
includes the genus Helicobacter, the family Campylobacteraceae and a number of 
other taxa (V andarnme et al., 1991 ). Figure 1.2 summarises our present understanding 
of the taxonomy of the genus Campylobacter. 
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Figure 1.2. Phylogenetic tree of rRNA clusters within Superfamily VI (Vandamme et 
al., 1995). 
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1.1.1.1 C. jejuni & C. coli 
The two clinically important and most frequently studied species of Campylobacter 
are C. jejuni and C. coli, initially called Vibrio jejuni and Vibrio coli (King, 1962). V 
jejuni was isolated from the faeces of cattle with diarrhoea (Laanbroek et al., 1977; 
Kreig, 1984). Organisms similar to V jejuni were also discovered in aborted sheep 
foetuses (Smibert, 1978). Subsequently V coli was isolated from the faeces of pigs 
with diarrhoea (Vandamme & Goossens, 1992). C. jejuni and C. coli are 
enteropathogenic to humans and are recognised as one of the most frequent causes of 
acute diarrhoeal diseases in humans throughout the world. They, however, occur 
mostly as commensals in sheep, cattle, pigs, poultry, birds, various domestic animals, 
rodents, apes and even insects (Skirrow, 1977; Blaser et al., 1980). 
C. jejuni is divided into two subspecies, C. jejuni subspecies jejuni and C. jejuni 
subspecies doylei (Steele & Owen, 1988). C. jejuni subsp. doylei differs from C. 
jejuni subsp. jejuni biochemically by the absence of nitrate reduction and often 
catalase activity, although a weak reaction may be observed (Table 1.1). The 
taxonomic separation of C. jejuni subsp. jejuni and C. coli can be problematic. The 
phenotype and genotype of both taxa are remarkably similar. The most common and 
reliable test used to distinguish between the two is the hippurate hydrolysis test: with 
the exception of some strains of C. jejuni subsp. jejuni, C. jejuni is positive and C. 
coli is negative (Table 1.1) (Harvey, 1980). Further tests used to distinguish the two 
species include hydrogen sulfide production in triple-sugar-iron agar, growth on a 
minimal medium (On et al., 1996) and utilization of propionate (Occhialini et al., 
1996). 
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Table 1.1 Differential diagnostic characteristics between Campylobacter species (Vandamme, 2000). 
Campylobacter Alpha- Hippurate Nitrate 
Species/subsp. hemolysis Catalase hydrolysis Urease reduction 
C.jejuni subsp. + + + - + 
ieiuni 
C. jejuni subsp. + V + - -
doylei 
C. coli V + - - + 
C. concisus V - - - V 
C. curvus V - V - + 
C. fetus subsp. - + - - + 
fetus 
C. fetus subsp. V v• - - + 
venerealis 
C. gracilis - V - - v• 
C. helveticus + - - - + 
C. V + - - + 
hyointeslinalis 
subsp. 
hyointestinalis 
C. V + - + + 
hyointestinalis 
subsp. lawsonii 
C. lari V + - V + 
C. mucosa/is - - - - -
C. rec/us + V - - + 
C. showae + + - - + 
C. soutorum0 + V - V + 
C. uosaliensis + - - - + 
• At least 80% of the strains examined contained this characteristic. 
b Including bv. sputorum, faecalis, and paraureolyticus. 
+ Characteristics present in over 90% of strains examined. 
- Charcteristics present in less than 11 % of the strains examined. 
V Strain-dependent reaction. 
Selenite H2SffSI lndoxyl Growth: 
reduction (trace acetate 
amounts) hydrolysis 25°C 42°c Minimal MacConkey 
medium 
V - + - + - -
- - + - - - -
+ V + - + + V 
V - - - V - -
- V V - V v• V' 
v• 
- - + v• V V 
- - - + - v· V 
- - V - V V v• 
- - + - + - -
+ + - V + V V 
+ + - - + V V 
V - - - + - -
- + - - + - v• 
- - + - V - -
- V V - V V + 
V + - - + V V 
+ - + - V - -
Resistance to: 
Glycine NaCl Cefoperazone Nalidixic Cephalothin 
(1%) (4%) (64 me/lit) acid 
+ - + - + 
V - - - -
+ - + - + 
V - - V -
+ - v• + -
+ - + + -
- - - V -
+ - - V -
V - V - -
+ - - + V 
V - V + -
+ - + V + 
V - V v• -
+ - - v• -
V - - - -
+ V - V -
+ - V - V 
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1.1.2 Habitats and Ecology 
Campylobacter spp. demonstrate considerable diversity in their ecology. They are 
ubiquitous in nature and can be isolated from anaerobic sludge, drinking water, 
seawater, birds, the genital and intestinal tracts of various animals and other sources 
(Table 1.2). 
Table 1.2 Bacteria of the genus Campylobacter and their associations. 
(Modified from Skirrow, 1994) 
Species / subspecies Main Host Association 
C. fetus subsp. fetus Sheep, cattle Ovine and bovine abortion; occasionally 
systemic infection in patients with immune 
deficiency 
subsp. venerealis Cattle Infectious infertilitv in cows 
C. hyointestinalis Pig, cattle Porcine proliferative enteropathy isolated 
occasionally from human patients with 
diarrhoea 
C. mucosa/is Pig Porcine proliferative enteropathy 
C. sputorum subsp. sputorum Man Gingival flora 
subsp. bubulus Cattle Genital flora, notably prepuce of bulls where 
it can be confused with C. fetus subsp 
venereal is 
C. concisus Man Gingival crevices; peridontal 
Disease 
C. curvus Man Gingival crevices; peridontal 
Disease 
C. rectus Man Gingival crevices; peridontal 
Disease 
C. showae Man Gingival crevices; peridontal 
Disease 
C. jejuni subsp. jejuni Birds, mammals Acute enterocolitis in man and some 
animals 
subsp dovlei Children with diarrhoea in developing world 
C. coli Pig, birds Acute enterocolitis in man 
C. /ari Birds, dog Intestinal commensals; occasionally 
associated with diarrhoea in man 
C. upsaliensis Dog, cat Dogs, cats and man, with and without 
diarrhoea; probablv pathogenic for man 
C. helveticus Dog, cat Dogs and cats, with and without diarrhoea 
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In cases of human infection, sources of contamination are mainly associated with 
milk and poultry products. Campylobacter have also been isolated from beef and 
pork. Campylobacters can survive in environments of temperatures as low as 4°C for 
several weeks and can also be present in surface water at higher temperatures. They 
have been found in natural water sources throughout the year. However, the presence 
of campylobacters does not clearly correlate with indicator organisms, such as 
Escherichia coli, for faecal contamination (Carter et al., 1987). 
As a result of this considerable diversity, many potential pathways of infection exist 
(Skirrow & Blaser, 1992). Generally the ecology of campylobacters focuses mainly 
on animal reservoirs where they reside in the intestinal tracts without causing clinical 
infection. Inanimate sources in the environment occur through contamination with 
animal faeces (NACMCF, 1993). 
1.1.2.1 Campylobacter in Pigs and Pork 
Studies carried out in the United States, Germany, Netherlands, Norway and Sweden 
have show that pigs are intestinal carriers of campylobacter species. Most 
campylobacter isolated from pigs are C. coli, however C. jejuni has also been isolated 
(Stem et al. , 1985; On, 1996). The presence of Campylobacter spp. in gallbladders 
and bile ducts of slaughtered pigs in Norway was described by Rosef (1981). He 
showed that 58% of the pigs sampled yielded Campylobacter spp. In another Nordic 
country, Sweden, Svedhem and Kaijser (1981) found that 95% of the pigs sampled at 
slaughterhouses yielded Campylobacter spp. A study carried out in the United States 
identified all campylobacter isolates from retail pork as C. coli (Stem et al., 1985), 
and in the United Kingdom, a two year study revealed that 3.4% of campylobacter 
isolates from retail pork were identified as C. jejuni and 96.6% as C. coli (Fricker & 
Park, 1988). C. jejuni and C. coli are however, not the only Campylobacter species 
isolated from pigs. Other species including C. hyointestinalis, C. mucosa/is, C. 
sputorum and C. hyoilei have been isolated from pigs but the incidence is less 
prevalent than is C. jejuni and C. coli (On, 1996). C. hyointestinalis, C. mucosa/is 
and C. hyoilei are commonly isolated from proliferative mucosal lesions in pigs with 
proliferative enteritis (porcine intestinal adenomatosis, PIA) (Gebhart et al. , 1983). 
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1.2 CLINICAL SIGNIFICANCE 
The clinical importance of Campylobacter to man was first suggested in 1946 by Levy 
who described an epidemic of gastroenteritis associated with the consumption of raw milk 
(Levy, 1946). In 1947, V fetus, later changed to C. fetus, was isolated from a pregnant 
woman who had suffered a septic abortion (Blaser & Reller, 1981). It was in 1972, that 
clinical microbiologists first isolated campylobacters from stool samples of patients with 
diarrhoea (Kist, 1985). It was the selective media developed in the 1970s that allowed for 
more laboratories to test stool specimens for Campylobacter (Butzler et al., 1973; 
Skirrow, 1977). Soon Campylobacter spp. were established as the common cause of 
human diarrhoea in most parts of the world (Allos & Blaser, 1995). In the United States, 
C. jejuni is now the leading cause of bacterial gastroenteritis (Tauxe, 1992). The Centers 
for Disease Control and Prevention/US. Department of Agriculture/Food and Drug 
Administration Collaborating Sites Foodbome Disease Activity Surveillance Network 
reported in 1996 that 46% of laboratory-confirmed cases of bacterial gastroenteritis were 
caused by Campylobacter spp. followed by Salmonella (28% ), Shigella (17%) and E. coli 
0157 (5%) (Figure 1.3). It is estimated that in the United States, there are between 2.1 to 
2.4 million cases of human campylobacteriosis each year (Altekruse et al., 1999). 
Cases 
500 
400 
300 
200 
100 
C Campylobacter D Salmonella • Shigella E. coli 0157 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Months 
Figure 1.3. Campylohacter and other foodborne infections; Centers for Disease Control and 
Prevention/U.S. Department of Agriculture/Food and Drug Administration Collaborating 
Sites Foodborne Disease Activity Surveillance Network, 1996 (Altekruse et al., 1999). 
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C. jejuni subsp. jejuni and C. coli have been recognised since the late 1970s as 
important agents of gastrointestinal infections throughout the world and are currently 
the leading causes of bacterial gastroenteritis, worldwide (Tauxe, 1992). More than 
95% of Campylobacter strains isolated and identified involved in cases of human 
disease have been C. jejuni subsp. jejuni or C. coli (Lastovica & Skirrow, 2000). 
However, of this 95%, C. jejuni accounts for 80-90% of infections, and 5-10% are due 
to C. coli. 
Campylobacter infection, or campylobacteriosis, is an acute diarrhoeal disease with 
clinical manifestations similar to those of other acute bacterial infections of the 
intestinal tract. Clinically it cannot be distinguished from salmonellosis or shigellosis. 
A diagnosis can be made only by the detection of campylobacters in stool samples 
from patients. There does not seem to be any significant difference between infections 
caused by C. jejuni and C. coli (Skirrow & Blaser, 2000). Commonly, symptoms 
include diarrhoea, fever and abdominal cramping. Bloody diarrhoea is not uncommon 
in Campylobacter infection. Other symptoms often present are nausea, headache and 
muscular pain. The illness usually occurs 2-5 days after ingestion of contaminated 
food, mainly undercooked chicken, or water and generally lasts 7-10 days. Relapses 
are not uncommon and occur in about 25% of cases (U. S. Food & Drug 
Administration, 2000). Human feeding studies have shown that consumption of as 
little as 500 bacteria can cause illness. Host susceptibility can dictate infectious dose 
to some degree (Black et al. , 1988). 
Campylobacter is one of the most common causes of foodbome disease in the United 
States. The vast majority of Campylobacter infections are not related to outbreaks but 
occur as sporadic individual infections. Common source outbreaks do occur which are 
normally small, consisting of less than 50 people. In Great Britain, 
campylobacteriosis is continually increasing. In 1998, 58,000 reported cases were 
recorded which far exceeds the reported cases of salmonellosis. Even though 
outbreaks due to Campylobacter spp. are rare, large-scale outbreaks have occurred 
such as one involving 2,500 children (Jones et al. , 1981) and one involving 2,000 
people in a town using a non-chlorinated water source as a water supply (U. S. Food 
& Drug Administration, 2000). Infections are acquired through consumption of 
contaminated food; water or unpasteurised milk, however chicken is the single most 
important vehicle of transmission for sporadic cases in the United States and other 
developing countries due to improper handling and preparation of poultry (Tauxe, 
1992). 
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Campylobacter infection plays an important role in the development of Quillian-Barre 
Syndrome (GBS). GBS, a neurological disorder resulting from demyelination of 
peripheral nerves can cause paralysis that leads to respiratory muscle failure and death 
(Nachamkin et al. , 1998; Allos, 1997a). GBS is the most common cause of acute 
neuromuscular paralysis, affecting 1 to 2 persons/I 00,000 population each year in 
many parts of the world (Blaser et al. , 1997). It is estimated that one case of GBS 
occurs for every 1,000 cases of campylobacteriosis and up to 40% of patients with 
GBS have evidence of recent Campylobacter infection (Allos, 1997b ). 
Campylobacteriosis has also been associated with reactive arthritis, bacteraemia, 
pancreatitis, haemolytic ureamic syndrome, and following septicaemia, infection of 
nearly any organ. Table 1.3 summarises Campylobacter associated diseases in 
humans. Fatality due to campylobacteriosis is rare in healthy individuals, usually 
occurring only in cancer or immunocompromised patients. The estimated case/fatality 
ratio of all C. j ejuni infections is 0.1 , or one death per 1,000 cases (U. S. Food & Drug 
Administration, 2000). 
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Table 1.3 Campylobacter and associated human and animal diseases. 
(Modified from On, 1996) 
Species Main source Human disease Animal disease 
or subspecies Association Association 
C. jejuni subsp. jejuni Birds, mammals Gastroenteritis, septicaemia, Gastroenteritis, avian 
Guillian-Barre syndrome heoatitis 
C. jejuni subsp. doylei Gastroenteritis, septicaemia, 
gastris 
C. fetus subsp. fetus Sheep, cattle Gastroenteritis, septicaemia Spontaneous abortion 
in ovine & bovine 
C. fetus subsp. Cattle Septicaemia Bovine infectious 
venereal is infertility 
C. coli Pig, birds, bulls, Gastroenteritis, septicaemia Gastroenteritis 
sheep 
C. lari Birds, dogs, cats, Gastroenteritis, septicaemia Avian gastroenteritis 
monkeys, horses 
C. hyointestinalis Pig, cattle, Gastroenteritis Porcine and bovine 
subsp. hyointestinalis hamster enteritis 
C. hyointestinalis Pigs 
subsp. lawsonii 
C. concisus Humans Periodontal disease, 
gastroenteritis 
C. mucosa/is Pigs Porcine enteritis 
C. curvus Humans Periodontal disease, 
gastroenteritis 
C. rec/us Humans Periodontal disease 
C. upsaliensis Dogs, cats Gastroenteritis, septicemia, Canine and feline 
abscesses gastroenteritis 
C. helveticus Dogs, cats Canine and feline 
gastroenteritis 
C. showae Humans Periodontal disease 
C. sputorum bv. Humans, cattle, Abscesses, gastroenteritis 
sputorum pigs 
C. sputorum bv. Cattle 
paraureo/yticus 
C. sputorum bv fecalis Cattle, sheep 
C. gracilis Humans Periodontal disease, deep 
tissue infection 
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1.2.1 Pathogenesis 
Although Campylobacter is recognised as one of the most important causes of human 
bacterial gastroenteritis, there is little knowledge of the pathogenesis of infection and 
controversy surrounds the number and specificity of toxic factors produced by these 
bacteria (Moutinho-Fragoso et al., 1998). The pathogenesis of Campylobacter 
infection involves both host- and pathogen-specific factors. The age and health of the 
host and specific humoral immunity from previous exposure will influence clinical 
outcome after infection (Blaser et al., 1987; Tauxe, 1992). There are many pathogen-
specific virulence determinants that may play a role in pathogenesis of infection, 
however, none has a proven role. Major virulence factors contributing to 
pathogenicity include chemotaxis, motility, toxin production and invasive properties. 
Motility by means of flagella is the best-studied virulence factor and is considered to 
be a major factor, allowing the organism to penetrate the mucous layer above target 
epithelial cells (Ketley, 1997). Initially the jejunum and upper ileum are the sites of 
infection, followed by spread and infection to the rest of the ileum and colon. Acute 
inflammatory changes in the mucosa take place, often with crypt abscess formation. 
It is important for the bacteria to reach and attach to the mucosa! surface. The spiral 
shape of campylobacters allows them to "corkscrew" their way through the thick 
mucous (Skirrow, 1994). Specific outer membrane proteins found in C. jejuni bind to 
epithelial cells (de Melo & Pechere, 1990), however, intact functioning flagella 
appear necessary for cell invasion (Grant et al., 1993). Once colonisation occurs, 
other possible virulence determinants are iron acquisition, host cell invasion, toxin 
production, inflammation and active secretion, and epithelial disruption with leakage 
of serosal fluid (Ketley, 1997). Many strains produce cholera-like enterotoxins but in 
much smaller amounts than Vibrio cholerae or enterotoxigenic Escherichia coli. 
Cytopathic toxins have been detected in the supernatant fluids of C. jejuni cultures. 
The significance is however unclear (Skirrow, 1994). Bacterial invasion of epithelial 
cells ultimately results in cellular injury and consequently loss of cellular function and 
diarrhoea. 
1.2.2 Treatment 
The majority of patients with Campylobacter enteritis require no treatment other than 
the replacement of fluids and electrolytes lost through diarrhoea and vomiting. 
Severely dehydrated patients should receive rapid volume expansion with intravenous 
fluids. Most cases of Campylobacter enteritis do not require antimicrobial treatment 
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due to the infections being brief, clinically mild, and self-limiting (Dryden et al. , 
1996). Antibiotic therapy is necessary for patients exhibiting high fever, bloody 
diarrhoea or more than eight stools in 24 hours; immunosuppressed patients, patients 
with bloodstream infections, and those with symptoms worsen or persist for more 
than 1 week from time of diagnosis. Antimicrobial therapy can reduce duration of 
illness, however delay in treatment may result in unsuccessful therapy. 
Erythromycin was the first antimicrobial agent used in treatment of Campylobacter 
infection. Erythromycin binds to the ribosome and appears to cause dissociation of the 
peptidyl-tRNA, rather than blocking the peptidyltransferase activity (Prescott & 
Baggot, 1993). Ease of administration, lack of serious toxicity, and high degree of 
efficacy makes erythromycin the drug of choice for C. jejuni infection (Altekruse et 
al., 1999). Resistance to erythromycin remains below 5% in most regions with 
exceptions such as Thailand where up to 50% of strains are resistant. C. coli isolates 
show a much higher level of erythromycin resistance than C. jejuni. Resistance to 
erythromycin in C. jejuni and C. coli is chromosomally mediated and is due to 
alteration of the ribosome (Taylor, 1992). Unfortunately cross-resistance exists 
between erythromycin and other macrolides (Skirrow & Blaser, 2000). 
Other antimicrobial agents particularly the fluoroquinolones and newer macrolides 
including azithromycin are also used. Fluoroquinolones such as ciprofloxacin, were 
introduced in the 1980s and hailed with great enthusiasm, as they were effective 
against most major pathogen causing bacterial enteritis and offered a new approach to 
antibiotic intervention. Fluoroquinolones had good in vitro activity against all 
Campylobacter species as well as against members of the family Enterobacteriaceae, 
however, resistance to fluoroquinolones emerged in Campylobacter and this will be 
discussed in Chapter 3. 
1.3 TYPING OF CAMPYLOBACTER 
Subtyping of Campylobacter spp. is an important requirement for epidemiological 
studies, especially for (i) tracing sources and routes of transmission of human 
infections, (ii) identifying and monitoring temporally and geographically specific 
strains with important phenotypic characteristics, and (iii) developing strategies to 
control organisms within the food chain (Arbeit, 1995; Nicol & Wright, 1998; Newell 
et al. , 2000). Accurate identification and typing of Campylobacter spp. is also 
important from a clinical aspect. No standard subtyping technique has been 
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established, however, speed, cost, and ease of use are important factors to consider. A 
variety of methods have been used, each with its own unique advantage or 
disadvantage over other subtyping methods (Table 1.4 ). 
Table 1.4 A comparison of genotyping methods and serotyping (Wassenaar & 
Newell, 2000). 
:\lethod Oiscr. T~·peability Reprod2 Speed Cost ,\vailability-. · · 
Powerl · , · 
fla typing reasonable3 1000/o good <l day low good 
PFGE good4 1000/oS good 2-3 days average limited 
ribotyping poor 1000/o good 3-4 average complex method 
-automated good NAV6 good NAV high limited 
RAPD Average 80% low <l low good 
AFLP Good 1000/o good 3-4 average complex method 
Sequencing very good 1000/o good 2-3 average limited 
Sero Aver e 80% ood7 <1 low limited 
1 Discriminatory power, is the ability to differentiate between genetically unrelated strains. 
2Reproducibility of the method determines how duplicate samples give reproducible 
results. This is not dependent on external factors such as genetic instability. 
3Horizontal exchange offlagellin sequences between strains may influence the 
discriminatory power of the method, however incidence that such exchange can take 
place outside the laboratory is limited to date. 
4Incidentally genomic instability is detected by PFGE which could lead to false 
interpretation, however the frequency of such events is unknown. 
5The sensitivity of PFGE is lower than 100% for DNAse producing strains, but this 
can be overcome by experimental modifications. 
6Not available. 
7weak serological cross-reactions can complicate the interpretation. Multiple passages 
may be required to fully express antigens. 
For epidemiological purposes the most widely used phenotypic procedure has been 
serotyping but this method usually lacks adequate discriminatory power. Many DNA 
based (genotypic) subtyping schemes have been developed including pulsed-field gel 
electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD) analysis, 
flagellin gene typing and ribotyping. Table 1.4 shows that most genotyping 
techniques have a higher typeability than serotyping. Often combinations of 
serotyping and genotypic techniques are used resulting in higher discriminatory power 
and therefore a more complete strain identification (Wassenaar & Newell, 2000). 
15 
1.3.1 Serotyping 
In the 1980s, two serological subtyping methods were developed. The Penner scheme 
is based on soluble heat-stable (HS) or somatic O antigen (Penner & Hennessey, 
1980) and the Lior scheme is based on variation in the heat-labile (HL) antigens (Lior 
et al., 1982). Currently there are 108 HL serotypes based on the bacterial 
agglutination technique of Lior et al., (1982) that are used to type C. jejuni and C. 
coli. The serotyping scheme by Penner and Hennessey identifies 47 heat stable 
serotypes of C. jejuni and 19 serotypes of C. coli. 
The Penner scheme has been more extensively used and forms the basis of the 
scheme developed in the Laboratory of Enteric Pathogens (LEP), Public Health 
Laboratory Services, United Kingdom. The LEP scheme now forms the basis of 
reference typing in the UK and was evaluated by using 2,407 C. jejuni and 182 C. coli 
isolates. Forty-seven serotypes were identified for C. jejuni and 15 serotypes were 
identified for C. coli. Non-typeability is a shortcoming of serotypic schemes. Using 
the LEP serotyping scheme, 19% of human isolates were non-typeable (Frost et al. , 
1998), with up to 63% of human isolates utilising the Penner scheme being non-
typeable from some countries (Asrat et al, 1997). Further disadvantages of serotyping 
include: it is labour intensive, time consuming and antisera required for typing are not 
widely available, limiting serotyping almost exclusively to reference laboratories. 
Despite these shortcomings, the Penner scheme of serotyping has been important in 
linking particular serotypes with GBS (Kuroki et al. , 1993; Goddard et al., 1997; 
Lastovica et al., 1997). Kuroki et al., (1993) confirmed the association between 
serotype 0: 19 Campylobacter isolates and GBS. Similarly, research by Yuki et al. 
(1997) also found that 0:19 strains were associated with GBS and that serotype 0:2 
was overexpressed in patients with Miller-Fisher syndrome (MFS), another 
neurological disorder. In South Africa, Goddard et al., (1997) and Lastovica et al., 
(1997) identified an additional serotype, 0:41, in patients with GBS. 
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1.3.2 Molecular Typing 
There is a well-recognised need for alternative subtyping schemes due to the 
limitations of serotyping. Only recently have molecular subtyping techniques been 
developed to address the shortcomings of phenotypic methods (Wassenaar & Newell, 
2000). Major advantages of genetically based methods are their enhanced sensitivity 
and discrimination. Genotyping methods have proved their worth as typing tools and 
are potentially available worldwide (Wassenaar & Newell, 2000). Genotypic 
techniques, such as pulsed field gel electrophoresis (PFGE), ribotyping and flagellin 
gene typing are currently being applied to epidemiological studies, especially from 
veterinary sources (Newell & On, 1998; Newell et al., 2000). 
1.3.2.1 Pulsed field gel electrophoresis 
PFGE is considered to be one of the most powerful tools available for microbial 
molecular epidemiology. The technique is highly sensitive in that whole genome 
restriction site polymorphisms are detected. The technique was described initially for 
C. jejuni (Yan et al., 1991) and was later adapted for C. coli, C. hyointestinalis, C. 
fetus and C. upsaliensis (Salama et al., 1992; Fujita et al., 1995; Bourke et al., 1996). 
PFGE requires bacterial cells to be embedded in agarose and lysed in situ to prevent 
DNA shearing, which would introduce random breaks. Extensive washing is carried 
out to remove contaminating chemicals such as formaldehyde that are used in cases to 
deactivate DNase activity of some thermophilic Campy/obacter strains. The intact 
DNA contained in an agarose slice is cleaved with an endonuclease and the restriction 
site polymorphisms are detected by PFGE. Restriction enzymes cleave the DNA 
infrequently, resulting in a few large fragments (20-200 kb). Restriction enzymes used 
include Smal, San and Kpnl for genotyping Campylobacter spp. The various DNA 
fragments obtained are separated by special electrophoretic conditions. Pulse electric 
fields are applied from different positions in the electrophoresis cell. 
Even though PFGE has a higher discriminatory power then other typing techniques, 
there are a number of disadvantages with PFGE: (i) the apparatus required for 
electrophoresis is specialised and expensive; (ii) preparation of the DNA-containing 
agarose blocks is tedious and time consuming; (iii) considerable variation in 
restriction enzymes and electrophoretic conditions between laboratories makes 
comparison of PFGE profiles difficult; (iv) genetic instability can lead to minor or 
major changes in profiles; (v) degradation of DNA due to DNase of some strains; and 
(vi) the DNA of different strains is undigestable with the enzymes used for PFGE. 
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1.3.2.2 Ribotyping 
Ribotyping makes use of the presence of multiple copies of the ribosomal RNA genes 
coding for 16S and 23S rRNA at different positions in the chromosome. These genes 
are suitable for targeting for subtyping purposes due to the strong conservation of 
regions within the rRNA genes between bacteria, and the presence of highly variable, 
non-coding, flanking regions. The most commonly used technique is Southern blot 
hybridisation of restricted DNA, hybridised with a probe specific for rRNA genes. 
The majority of researchers use probes derived by PCR from Campylobacter DNA 
and specific for 16S rRNA (Wassenaar & Newell, 2000). Most Campylobacter spp. 
have three ribosomal gene copies, fewer than other bacteria which reduces the 
discriminatory power. Generally, ribotyping is best suited for speciation of 
Campylobacter isolates difficult to identify phenotypically (Kiehlbauch et al., 1991), 
although the technique has successfully been applied to differentiate between C. jejuni 
in an outbreak situation (Tee et al., 1992). Subtyping of C. coli (Stanley et al. , 1995), 
C. upsaliensis (Goossens et al. , 1995), C. lari (Owen et al. , 1993a) and C. helveticus 
(Kiehlbauch et al. , 1991) has also been achieved. 
Ribotyping is unsuited as a routine genotyping procedure due to its low 
discriminatory power and it is a laborious, time-consuming technique. Development 
of a completely automated ribotyping procedure for identification and characterisation 
of bacteria enhances reproducibility and saves time. However, the high costs of 
equipment and consumables limits the use of this technology. 
1.3.2.3 Randomly amplified polymorphic DNA 
Randomly amplified polymorphic DNA (RAPD) is a PCR based fingerprinting 
technique (Welsh & McClelland, 1990; Williams et al. , 1990). Arbitrarily designed 
primers are used for the amplification of random DNA products under low-stringency 
conditions. The method uses the entire genome of the target organism to generate 
amplified fragments . The number and size of the fragments generated are partially 
controlled by stringency regulation through manipulations of the annealing 
temperature. RAPD does not require prior knowledge of the target DNA sequence 
unlike other PCR based typing methods, such as flagellin gene typing. Amplification 
varies due to the length of the product formed and the efficiency of annealing, 
resulting in banding patterns consisting of stronger and weaker amplicons of variable 
length. Banding patterns obtained are suitable for comparison of isolates within a 
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bacterial species. RAPD has been applied to typing human, animal and environmental 
isolates of C. jejuni, C. coli and C. Zari (Madden et al. , 1996). A slight variation to the 
amplification of random genomic DNA fragments is the use of primers specific for 
enterobacterial repetitive intergenic consensus sequences (ERIC) (Sharples & Lloyd, 
1990). ERIC primers can be used under high stringency to match the target sequences. 
This method has been used to genotype C. jejuni, C. upsalienesis (Giesendorf et al. , 
1994) and C. coli in pigs (Weijtens et al., 1999). 
RAPD has the advantage of being much quicker and cheaper than PFGE and does not 
require complex apparatus. However, problems have been associated with 
reproducibility. Meunier and Grimont, (1993) noted that the source of Taq DNA 
polymerase and type of thermocycler could significantly affect the patterns obtained. 
Standardised conditions are now more readily available following improvements in 
thermocylers and commercially prepared reagents (Newell et al. , 2000). 
1.3.2.4 Amplified fragment length polymorphism 
Amplified fragment length polymorphism (AFLP) was originally developed for the 
genetic analysis of plants (Vos et al., 1995) and has been adapted for genotyping of 
bacteria (Lin & Kuo, 1995; Janssen et al. , 1996). AFLP has proven to be a useful 
typing tool for Campylobacter (Duim et al. , 1999; Kokotovic & On, 1999). 
The method involves chromosomal DNA digestion with two restriction enzymes. The 
enzymes of choice are dependant on the G+C content and the size of the genomic 
DNA. Amplification by PCR of the digested products is based on the restriction sites 
and designed such that only those fragments flanked by both restriction sites are 
amplified. The primers are either radioactively labelled (Vos et al. , 1995) or 
flourescently labelled (Kokotovic & On, 1999). The labelled PCR products are 
analysed on denaturating polyacrylamide gels. Optimally 80-100 bands are generated 
which can be reduced by incorporation in the PCR primers, of one or more specific 
nucleotides adjacent to the restriction site. Therefore only fragments with specific 
nucleotides adjacent to restriction site will be detected and analysed (Wassenaar & 
Newell, 2000) on an automated DNA seqeuncer. 
AFLP has been successfully used for the differentiation between isolates of H pylori 
and Campylobacter (Gibson et al., 1998; Kokotovic & On, 1999) and has recently 
been developed for subtyping C. jejuni. AFLP has also been successfully used to 
investigate the epidemiology of poultry Campylobacter (Duim et al. , 1999). An 
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advantage of this technique is that single nucleotides can be resolved. AFLP is rapid 
and easily standardised, however the equipment is expensive. With the digitisation of 
AFLP results, accurate interpretation, ease of data storage and data exchange between 
research institutes is possible. 
1.3.2.5 Flagellin gene typing 
Flagellin gene typing (Ila typing) was developed by Nachamkin et al. , (1993) for sub-
typing C. jejuni (Nachamkin et al. , 1993); subsequently the technique has been 
applied to typing other Campylobacter spp. (Owen et al., 1993b). Flagellin is the 
major protein subunit of the flagellar filament involved in motility. The flagellin gene 
locus of C. jejuni comprises two flagellin genes, flaA andflaB, which are arranged in 
tandem repeats and separated by a 170 bp intergenic region. These genes are highly 
conserved, with 95% identity between flaA and flaB genes in individual isolates 
(Nuitjten et al. , 1990). Due to both highly conserved and variable regions that are 
present (Meinersmann et al., 1997), the flagellin gene locus is suitable for restriction 
fragment length polymorphism (RFLP) analysis of a PCR product. PCR targets either 
the flaA or both the flaA and flaB genes for amplification by use of conserved 
primers. The amplicons are digested with restriction enzymes resulting in fragments 
that can be analysed by agarose gel electrophoresis (Ayling et al. , 1996; Nachamkin 
et al. , 1993; Nachamkin et al. , 1996). Variations between strains will be reflected by 
differences in enzyme recognition sites present in less conserved regions of the PCR 
product. 
At least 7 fla typing methods that have been developed (Alm et al. , 1993a; Ayling et 
al. , 1996; Birkenhead et al. , 1993; Burnens et al. , 1995 King & Clayton, 1991 ; 
Nachamkin et al. , 1993; Nishimura et al., 1996) with considerable differences in the 
PCR/RFLP method (Table 1.5). Differences include DNA preparation, primer design, 
restriction enzymes used, annealing temperature and nomenclature of genotype. 
Differences between the primers can result in significant variation in the profiles 
obtained from the same strains. The majority of the primer sets have been designed to 
amplify flaA specifically (Burnens et al. , 1995; Nachamkin et al. , 1993; Nishimura et 
al., 1996), however some methods make use of amplification of both the flaA and 
flaB using combinations of three primers (Alm et al. , 1993a; Ayling et al. , 1996; King 
& Clayton, 1991) (Table 1.5). 
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Table l.S A summary of flagellin gene typing methods for Campylnbacter. 
(Modified from Matsheka, 2000) 
Reference Species Primers PCR product 
typed and size 
Forward 5'"""7 3' Reverse 5' """7 3' 
Alm eta/., C.jejuni 5' ATGGGATrfCGTATTAAC 5' GCACC[CT]TTAAG[AT] jlaA andjlaB 
(1993a) C. coli 3' GT[AG]GTT ACACCTGC 3' 1448bp 
5' AAGGATrf AAAA TGGGTT 
TTAGAATAAACACC 3' 
Ayling et al., C.jejuni 5' AAAGGATCCGCGTATTAA 5' GATrfGTTATAGCAGTT jlaA andjlaB 
(1996) CACACAAATGTTGCAGC3 ' TCTGCT AT ATCC 3' 1490bp 
5' AAAGGATCCGAGGATAAA 
CACCAACATCGGT 3' 
Bumens et al., C.jejuni 5' ccggatcccATGGCATTTCGTA 5' ttcgaattCT A TTGT AA T AA jlaA 
(1995) C. coli TT 3' TCTTAAAACAT 3' 173lbp 
King & Clayton, C.jejuni 5' ATGGGATrfCGTATTAAC 5' CTATTGTAATAATCTTA jlaA andjlaB 
(1991) AC 3' AAA 3' 1723bo 
Nachamkin et al., C.jejuni 5' GGATrfCGTATTAACACA 5' CTGTAGTAATCTTAAAA jlaA 
(1993, 1996) C. coli AATGGTGC3' CATTTTG3 ' 1728bp 
Nishimura et al., C. jejuni 5' TACTACAGGAGTTGAGCT 5' GTTGATGTAACTTGATT jlaA 
(1996) T3 ' TTG3 ' 702bp 
Restriction 
enzyme 
Pstl, EcoRI 
Ddel, Alul, 
Hinfl 
Alul, Ddel, 
Haem Hinfl 
HaellI, Bgfil 
Ddel 
Haem, A/al, 
Mbol 
Regions of DNA homology are indicated in red (forward primers) and blue (reverse primers). Sequences utilised for cloning 
shown by lower case nucleotide bases. 
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As a result of the high conservation between flaA and flaB, addition of a flaB 
specific primer only contributes to differentiation in less than 10% of isolates (Alm et 
al., 1993b; Mohran et al., 1996). Most of the forward primers designed match the start 
of the flaA gene with slight variation between methods. The reverse primers however 
vary resulting in different sized PCR products (Table 1.5). Choice of restriction 
enzyme varies significantly between studies. The enzymes currently in use include 
Ddel, Hinjl, Alul, EcoRl and Pstl. Ayling et al., (1996) report that the enzyme Ddel 
provides the best discriminatory power that can be enhanced by use of Hinfl in 
combination. 
flaA typing is a useful tool for subtyping clinical and epidemiological investigations 
(Nachamkin et al., 1993). It is quick, simple and has a high level of discrimination. 
The technique has been applied to Campylobacter from broiler flocks, foodstuffs and 
from animals and water (Ayling et al., 1996; Lorenz et al. , 1998). The method has 
also been applied as an epidemiological tool to investigate human isolates clustered 
by Penner serotyping (Slater & Owen, 1998) as well as strains associated with GBS 
(Fujimoto et al., 1997). However there are disadvantages with this method. The 
choice of primer sets, combined with the variation of PCR parameters make 
comparison of results between research institutes difficult unless standardisation of 
the flagellin typing technique occurs. 
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1.4 AIMS OF THE STUDY 
Recently, fluoroquinolone resistant Campylobacter coli were isolated from a pig farm 
in Stellenbosch, South Africa. Fluoroquinolones were introduced into veterinary 
medicine in South Africa approximately 6 years ago. Since then there has been a 
steady increase in resistant isolates. C. coli is the most frequently isolated species of 
Campylobacter from pigs. The emergence of porcine fluoroquinolone resistant C. coli 
isolates is cause for concern as pigs are a food source and may be a source of resistant 
strains in humans. 
Therefore the aims of this project are two fold: 
1 ). To study the epidemiology of sensitive and resistant isolates using 
serotyping and molecular typing. 
2). To determine the molecular basis of fluoroquinolone resistance in C. coli. 
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2.1 INTRODUCTION 
C. coli and C. jejuni are considered to be among the most important enteric pathogens 
worldwide. While C. jejuni is commonly isolated from chickens, C. coli is the 
dominant species isolated from pigs. Campylobacters were first described in pigs in 
1944 by Doyle, who thought they were the cause of swine dysentery (Doyle, 1944). 
He thought the organism was a vibrio and so proposed the name " Vibrio coli", which 
was subsequently changed to C. coli (Laanbroek et al., 1977; Kreig, 1984). The 
principal agent of swine dysentery is in fact Serpulina (Treponema) hyodysenteriae, 
although there is evidence that anaerobic bowel flora and C. coli may play a role in 
pathogenesis of the disease (Fernie et al. , 1975). There has been debate over whether 
C. coli alone is enteropathogenic for pigs with reports of its presence in large numbers 
and as the sole putative pathogen in the intestines of pigs with diarrhoea, however it is 
also found in most healthy pigs (Skirrow, 1994). 
Numerous epidemiological reports describe food of animal origins as sources of 
campylobacteriosis in humans. Poultry is the main link with Campylobacter infection 
and has often been associated with outbreaks of campylobacteriosis (Skirrow et al. , 
1981 ). In contrast, pork has been implicated in a limited number of outbreaks 
(Y anagisawa, 1980). Although pigs are a natural reservoir of campylobacters, not 
much is known about their epidemiology in these animals. On the other hand, many 
epidemiological studies have been carried out on C. jejuni in chickens. 
In the recent past, serotyping has been used to study the epidemiology of 
Campylobacter. The two schemes used for epidemiological studies are based on heat-
stable antigens (Penner & Hennessey, 1980), and heat-labile antigens (Lior et al., 
1982). These methods have proved valuable and have tended to be the "gold 
standard" for typing (Wassenaar & Newell, 2000); however, they are limited as not all 
isolates can be serotyped, and specific antisera are of limited availability. 
Furthermore, isolates of the same serotype may be heterogenous and only 
distinguishable by additional typing methods (Owen et al., 1995). Due to such 
problems, the need for an alternative subtyping technique was recognised. In 1993 , 
Nachamkin et al. , (1993) developed a molecular typing technique for C. j ejuni 
utilising restriction fragment length polymorphism (RFLP) of the flaA gene. The 
results suggested that the method was sufficiently discriminatory and could provide 
an alternative to serotyping as a typing method for clinical and epidemiological 
investigations (Nachamkin et al. , 1993). Ayling et al. (1996) developed a similar PCR 
approach that they applied to veterinary epidemiological investigations for subtyping 
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C. jejuni isolates. The method was validated by using strains from 28 serotypes of C. 
jejuni and was stated to be suitable for typing C. coli (Ayling et al., 1996). The 
method was optimised for isolates of C. jejuni and was used to investigate 
campylobacters from chickens in 15 broiler flocks . The potential value of this 
technique as a typing tool for veterinary epidemiology investigations was determined 
by comparing it with the Penner serotyping scheme. All the isolates could be subtyped 
using the RFLP method and no direct relationship between serotype and RFLP was 
observed. The RFLP/PCR typing method utilising the flagellin genes provides a 
suitable tool for the investigation of the routes of transmission and sources of 
campylobacters in chickens (Ayling et al., 1996). Burnens et al. , (1995) looked at the 
relationship between Lior heat-labile serogroups of C. jejuni and C. coli and the RFLP 
of the flagellar genes to determine if any possible correlation existed. Limited 
correlation between flagellar RFLP and the Lior serogroup existed (among 85 
seroreference strains, 74 different RFLP patterns were observed) with flagellar gene 
RFLP providing a marker that was highly discriminatory between serotypes (Burnens 
et al. , 1995). Based on the above and the observations of others as shown in Table 
1.4, flaA typing has been used successfully to type Campylobacter spp. including C. 
coli. 
This chapter describes the typing of porcine isolates of C. coli using the Penner 
scheme of serotyping in conjunction with the molecular technique,flaA typing. 
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2.2 EXPERIMENTAL PROTOCOL 
2.2.1 Bacterial Isolates and Susceptibility Testing 
Rectal swabs were taken from pigs at a pig farm in Stellenbosch, South Africa, in 
October and December, 1999. Campylobacters were isolated from the swabs taken by 
Dr. T. Gous of the Regional Veterinary Laboratories Stellenbosch. Isolates were 
identified as C. coli by E. Le Roux using morphological and biochemical 
characteristics consistent with the genus Campylobacter. Sixty one isolates were 
included in the study. A reference strain, C. coli NCTC 11283, was kindly provided 
by Dr. A. Lastovica, Red Cross Children' s Hospital, Cape Town and the Department 
of Medical Microbiology, University of Cape Town, Cape Town. Disc susceptibility 
testing using nalidixic acid (30 µg) and ciprofloxacin (5 µg) was carried out according 
to the National Committee for clinical Laboratory Standards criteria (National 
Committee for Clinical Laboratory Standards criteria, 1998a). 
2.2.1.1 Culture Maintenance 
C. coli samples were plated onto tryptose blood agar (TBA) plates containing 10% 
unlysed horse blood. Cultures were incubated for 2 days at 3 7°C in a H2-enhanced 
microaerophilic atmosphere generated by use of Oxoid BR 38 gas generating kit. 
Short term storage (less than 7 days) plates were stored under microaerophilic 
conditions at 3 7°C or stored at 4 °C. 
Long term storage, bacteria were scraped off the TBA plates and resuspended in 
glycerol broth (1ml of 30% v/v glycerol, 70% 2x YT broth (Appendix A)) and stored 
at -70°C. 
2.2.2 Preparation of Genomic DNA 
Two methods were used to isolate DNA. 
2.2.2.1 Genomic DNA Extraction Kit Method 
Genomic DNA was extracted using the Wizard® Genomic DNA Purification Kit 
(Promega). Campylobacter cells were harvested from TBA plates and gently 
resuspended in 600 µl of Nuclei Lysis Solution (Promega). The resuspension was 
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incubated at 80°C for 5 minutes allowing for lysis of the cells. Contaminating RNA 
was removed by the addition of 3 µl of RNase solution (200 µg/ml) , at 37°C for 1 
hour. The sample was cooled to room temperature (RT), 200 µl of Protein 
Precipitation Solution (Promega) was added, vortexed and the sample was placed on 
ice for 5 minutes; after which it was centrifuged (Eppendorf 5417C benchtop 
centrifuge) at 14,000 rpm for 4 minutes to remove cellular protein. The clear lysate 
was removed and the DNA was recovered, following the addition of isopropanol (600 
µl), by centrifugation at 14,000 rpm for 2 minutes. The DNA pellet was washed with 
70% ethanol and allowed to dry for 10-15 minutes. The DNA pellet was rehydrated 
by the addition of 100µ1 of DNA Rehydration Solution (10 mM Tris-HCl, 1 mM 
EDTA) and incubated for 1 hour at 65°C to facilitate the process. The DNA solution 
was stored at -20 °C. 
2.2.2.2 Guanidium Thiocyanate DNA Extraction 
Genomic DNA was extracted by use of guanidium thiocyanate method (Pitcher et al. , 
1989). Campylobacter cells were harvested and resuspended in 100 µl of Tris-EDT A 
(TE) buffer (Appendix A) and lysed with 500 µl of guanidium thiocyanate solution 
(Appendix A). The solution was vortexed briefly and placed on ice when lysis was 
evident. Ice cold (250 µl) 7.5M ammonium acetate (Appendix A) was added to the 
solution, mixed and left on ice for 10 minutes. Five hundred microlitres of 
chloroform-isoamylalcohol (Appendix A) was added and the solution was centrifuged 
(Eppendorf 5417C benchtop centrifuge) at 10,000 g for 10 minutes. The supernatant 
was added to a 0.54 volume of ice-cold isopropanol, mixed and briefly centrifuged to 
collect the DNA. The pellet was washed 3 times with 70% ethanol to remove traces of 
guanidium thiocyanate. The ethanol was drained and the pellet air-dried and 
resuspended in 100 µl of TE buffer. 
2.2.3 DNA Concentration Determination 
Genomic DNA concentration was determined by agarose gel electrophoresis and by 
UV spectrophotometry. Aliquots of sample DNA were electrophoresed next to titrated 
concentrations of lambda-DNA (A-DNA) (Promega) commencing with 50 ng. DNA 
concentration was estimated by comparison with A-DNA of known concentrations. 
UV spectrophotometry was used to determine DNA concentration of genomic DNA. 
The DNA was diluted 100-fold and the DNA concentration was determined by 
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measuring the absorbance at 260 nm in a Hewlett Packard Diode Array 
Spectrophotometer using the HP 8452 Win System and the 1 unit to 50 mg/ml 
relationship. DNA was diluted to approximately 200 ng/µl for use in later 
applications. 
2.2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was carried out in submerged 0.8-1.5% agarose gels 
(Techcomp, Ltd.) dissolved in Ix Tris-acetate (TAE) buffer (Appendix A). The 
migration rate of DNA is dependent on the molecular size of the DNA, the agarose 
concentration and the DNA conformation (Maniatis et al., 1982). Negatively charged 
DNA migrates from the anode to the cathode when an electric field is applied across 
the gel. To visualise the DNA, ethidium bromide (EtBr) (Appendix A) was added to 
the agarose solution at a concentration of 20 ng/ml and to monitor migration, sample 
DNA was mixed with tracking dye (2 µl) (Appendix A). Samples were loaded into 
wells and electrophoresed next to a molecular weight marker, 1kb DNA ladder 
(Promega) (Appendix B). DNA was visualised under an ultra violet light source (302 
nm) and photographed using a Kodak Digital DC 120 camera. 
2.2.5 Serotyping 
Serotyping of the 61 pig isolates was carried out with Dr. Lastovica on the basis of 
the thermostable somatic (0) lipopolysaccharide antigens performed with antisera to 
the 66 serotype reference strains of C. jejuni and C. coli by the scheme of Penner & 
Hennessy (1980). Isolates were also tested against an additional 12 antisera to new 
serotypes not included in the scheme (Le Roux & Lastovica, 1998). 
The passive haemagglutination technique was used for titration of antisera. For 
antisera titration with saline extracted or EDTA-extracted antigens, extracts were 
diluted 1: 10 in phosphate-buffered saline (PBS) (Appendix A). Diluted extracts were 
incubated at 3 7°C for 1 hour with an equal volume of a 1 % suspension of sheep 
erythrocytes washed previously in PBS. Centrifugation of the sensitised erythrocytes 
was followed by three washes in PBS and cells were resuspended in PBS to a final 
concentration of 0.5%. Two fold dilutions were prepared in a microtitration plate with 
wells containing 0.025 ml of PBS. To each well of diluted antisera, 0.025 ml of 
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sensitised erythrocytes was added. Plates were shaken and incubated for 1 hour at 
37°C and stored at 4°C overnight. Plates were read by examining for agglutination of 
erythrocytes. The highest dilution of antiserum exhibiting agglutination was taken as 
the titre. Antisera were initially diluted 1 :40 and absence of agglutination at this 
dilution was taken as a negative reaction (Penner & Hennessy, 1980). 
2.2.6 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was used to amplify DNA sequences of interest. 
Amplification occurs in the presence of dNTPs, lx PCR buffer, Taq polymerase and 
two oligonucleotide primers. Primers are designed to be complementary to sequences 
flanking the target DNA segment. PCR reaction involves the denaturation of the 
original double-stranded DNA sample at high temperature, followed by annealing of 
the primers to the DNA template at an appropriate temperature. Extension of the 
primers occurs by use of a thermostable DNA polymerase, Taq polymerase. These 
steps are repeated in cycles resulting in the exponential synthesis of target DNA (Fig 
2.1 ). (Saiki et al., 1988). 
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Figure 2.1 Schematic diagram of polymerase chain reaction (PCR) (Garrett & 
Grisham, 1995). 
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2.2.6.1 16S rRNA Gene Amplification 
To determine the suitability of template DNA for PCR, the 16S rDNA was amplified 
using primers designed to amplify a 1,004 hp fragment within the coding region of the 
16S rRNA gene in Campylobacter, Arcobacter and Helicobacter (Marshall et al., 
1999). The forward and reverse primers used were CAH 16S la (5 ' -
AATACATGCAAGTCGAACGA-3 ') and CAH 16S lb (5 '-
TTAACCCAACATCTCACGAC-3' ), respectively. Primers were synthesized by 
GIBCO-BRL (Life Technologies). The 16S PCR amplification method was 
performed in a 50 µl reaction volume containing approximately 200 ng DNA, 0.5 µM 
each primer, I x PCR buffer (100 mM Tris-HCl (pH 8.3), 500 mM KCl, 15 mM 
MgCh, 0.01 % (w/v) gelatin (TaKaRa), 200 µM of each dNTP (TaKaRa), 2.5 units 
Taq polymerase (TaKaRa). PCR amplification was performed in a Perkin Elmer 
GeneAmp PCR System 2400. Initial denaturation was carried out at 95°C for 120 
seconds, followed by 30 amplification cycles, each consisting of 94°C for 60 seconds, 
52°C for 45 seconds and 72°C for 120 seconds. A final primer extension at 72°C for 
10 minutes was included. Aliquots (10 µl) of PCR products were electrophoresed on a 
1.5% agarose gel at 100V for 1 Vi hours. 
2.2. 7 Molecular Typing 
2.2.7.1 Flagellin Gene (/1.aA) Typing 
A number of sets of primers were used to amplify the flaA gene of C. j ejuni and C. 
coli (Table 2.1 ). Figure 2.2 is a schematic diagram of the flaA gene showing primer 
binding sites. 
Table 2.1 Primers used in the amplification ofjlaA. 
Pnml·r On, 111.111011 'l'l11H'IHl.' I.:;,' >J 0 1 lfrkn·11ll' 
If ,11 I\ ,II d f{l•q·r,l'I 
Cj 431 Forward AAAGGATCCGCGTA1TAACACAAATG1TGCAGC Ayling et al. 
(1996) 
Cj 433 Reverse GAT1TG1TATAGCAGT1TCTGCTATATCC Ayling et al., 
(1996) 
Cc431 Forward 1TCGTA1TAACACAAATG1TGC This studv 
Cc433 Reverse CGTGCGCTAGATACTATCTG This studv 
A2 Reverse CTGTAGTAATC1TAAAACATT1TG Nacharnkin et 
al., (1993) 
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Cj 431, bases 92-114 
Cc 431, bases 92-111 
5' 
.. 
Cc 433, bases 1560-1579 
A2, bases 1705-1728 
Figure 2.2 A schematic representation ofthejlaA primer binding sites. The primers (arrows) and 
their target sites (bases) are shown. Primers are not drawn to scale. 
PCR amplifications were performed in solutions containing 1 Ox PCR buffer ( 100 mM 
Tris-HCl (pH 8.3), 500 mM KCl, 15 mM MgCli, 0.01% (w/v) gelatin (TaKaRa); 2.5 
mM of each dNTP (TaKaRa); 20 pmol of each primer; 2.5 units Taq polymerase 
(TaKaRa); 200 ng of genomic DNA; and ultrapure water made up to a final volume of 
50 µI. A control solution was used in which ultrapure water was used in place of 
genomic DNA The initial denaturation was at 94 °C for 60 seconds, followed by 45 
cycles of 94°C for 45 seconds, 50°C for 45 seconds and 72°C for 120 seconds. A final 
extension took place at 72°C for 5 minutes. Aliquots of the PCR products were gel 
(1.5%) electrophoresed (100V for 1 Yillf) and visualised by UV transillumination. 
2.2.7.2 RFLP Analysis 
Restriction digestions (20 µl) containing an aliquot (8 µI) of the PCR products was 
digested with Ddel (10 units) (GibcoBRL ®, Life Technologies) at 37°C overnight in 
the buffer reaction conditions specified by the manufacturer. The enzymatic reaction 
was stopped by the addition of6x tracking dye (Appendix A). Following digestion, he 
fragments were separated in a 2.5% agarose gel at 30V for 16 hours. 
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2.3 RESULTS 
2.3.1 Campylobacter Isolates 
The 61 porcine isolates used in this study are shown in Table 2.2: 55 of the strains 
(2R-73R) came from pigs on farm A and were isolated in October 1999. The 
remaining isolates (2MF2034-10MF2039) were obtained in December 1999 from pigs 
on farm B, the source of pigs for farm A. Disc susceptibility testing showed that 57% 
(35/61) of the strains were resistant to ciprofloxacin and nalidixic acid. Resistant and 
sensitive strains were isolated from 15 pigs on farm A (Table 2.2). Paired resistant 
and sensitive strains were not isolated from individual pigs on farm B. 
Table 2.2 Serotyping and disc susceptibility testing of porcine isolates of C. coli 
Sample Lab Number Species Serotype Antibiotic Resistance (S or 
mt 
Nalidixic Ciprofloxacin 
Acid 
Farm A: 
2R 1754 C. coli 0 :5 R R 
4R 1755 C. coli 0 :30 R R 
6R 1756 C. coli 0 :59 R R 
7S 1757 C. coli 0 :59 s s 
8S 1758 C. coli NT2 s s 
IOR 1760 C. coli 0 :5 R R 
llR 1761 C. coli 0:48 R R 
14R 1763 C. coli 0 :5 R R 
22S 1766 C. coli 0 :59 s s 
23R 1767 C. coli 0 :24 R R 
26R 1769 C. coli NT R R 
39S 1771 C. coli 0:34 s s 
40R 1772 C. coli NT R R 
42S 1773 C. coli 0 :30 s s 
43R 1774 C. coli 0 :24 R R 
47S 1776 C. coli NT s s 
49S 1777 C. coli NT s s 
54R 1779 C. coli 0 :24 R R 
55R 1780 C. coli NT R R 
59R 1783 C. coli 0 :24 R R 
65S 1786 C. coli NT s s 
66R 1787 C. coli 0 :5 R R 
67R 1788 C. coli 0 :5 R R 
69S 1790 C. coli NT s s 
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71R 1792 C. coli 0 :5 R 
12S 1762 C. coli NT s 
12R 1762 C. coli NT R 
19S 1764 C. coli NT s 
19R 1764 C. coli 0 :34 R 
20S 1765 C. coli 0 :48 s 
20R 1765 C. coli 0 :48 R 
24S 1768 C. coli 0 :54 s 
24R 1768 C. coli 0 :24 R 
38S 1770 C. coli NT s 
38R 1770 C. coli 0 :24 R 
46S 1775 C. coli 0 :34 s 
46R 1775 C. coli 0 :24 R 
53S 1778 C. coli NT s 
53R 1778 C. coli 0 :24 R 
57S 1781 C. coli NT s 
57R 1781 C. coli 0 :24 R 
58S 1782 C. coli NT s 
58R 1782 C. coli 0 :5; 0 :24 R 
60S 1784 C. coli 0:30 s 
60R 1784 C. coli NT R 
62S 1785 C. coli NT s 
62R 1785 C. coli 0 :24 R 
68S 1789 C. coli NT s 
68R 1789 C. coli 0 :5; 0 :30 R 
70S 1791 C. coli NT s 
70R 1791 C. coli 0 :5 R 
72S 1793 C. coli 0 :34 s 
72R 1793 C. coli 0 :24 R 
73S 1794 C. coli NT s 
73R 1794 C. coli NT R 
FarmB: 
2MF2034 2034 C. coli 0 :59 R 
3MF2035 2035 C. coli 0 :39; 0 :47 R 
5MF2036 2036 C. coli 0 :54 s 
7MF2037 2037 C. coli NT s 
9MF2038 2038 C. coli 0 :48 R 
10MF2039 2039 C. coli NT R 
1 Antibiotic Resistance: disc susceptibility testing, sensitive (S) or resistant (R) 
2 Non-Typeable (NT) 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
s 
R 
R 
R 
s 
s 
R 
R 
The paired sensitive and resistant isolates from the same pigs are shown between the two, thick black 
lines. 
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A number of serotypes, including mixed serotypes, were identified in the 61 strains. 
The predominant serotypes were 0:24 (11/61) and 0:5 (7 /61). A feature of isolates 
identified in this study as serotypes 24 and 5 is their uniform resistance to 
ciprofloxacin and nalidixic acid. Serotypes (0:48, 0:54 and 0:59) identified in strains 
from farm B were also identified in strains from farm A A high number of the strains 
were non-typeable (23/61). With respect to resistant and sensitive strains isolated 
from the same pig: only one pair (20R and 20S) had the same serotype (0:48). A 
summary of serotypes and the number of strains with each type are shown in Table 
2.3. 
Table 2.3 Samples within each serotype. 
NT1 8S 
I2R 
12S 
19S 
26R 
38S 
40R 
47S 
49S 
53S 
55R 
57S 
58S 
60R 
62S 
65S 
68S 
69S 
70S 
73R 
73S 
7MF2037 
I0MF2039 
24 23R 
24R 
38R 
43R 
46R 
53R 
54R 
57R 
59R 
62R 
72R 
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Table 2.3 continued. 
...,,., ot~ pt· "ample 
5 2R 
lOR 
l4R 
66R 
67R 
70R 
71R 
34 l9R 
39S 
46S 
72S 
48 llR 
20S 
20R 
9MF2038 
59 6R 
7S 
22S 
2MF2034 
30 4R 
42S 
60S 
24S 
5MF2036 
5; 24 58R 
5; 30 68R 
39; 47 3MF2035 
1 Non-typeable 
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2.3.2 Suitability of DNA Template for PCR 
Prior to carrying out PCR experiments for flaA typing and other PCR based methods 
[Chapter 3], the suitability of extracted genomic DNA for PCR application was 
investigated using 16S rDNA PCR. Using primers specifically for the coding region 
of the 16S rRNA gene of Campylobacter, Arcobacter and Helicobacter (Marshall et 
al. , 1999), a 1,004 bp fragment was amplified from all of the samples, indicating the 
suitability of the template for PCR application. Figure 2.3 shows PCR products 
obtained from some of the strains. 
Figure 2.3 Amplification of 16S rRNA gene using Campylobacter, Arcobacter and 
Helicobacter specific primers. Lane 1, Molecular weight marker 1 kb DNA ladder 
(Promega); lane 2, positive control C. jejuni; lane 3, C. coli NCTC 11283; lane 4, 53S; lane 5, 
62R; lane 6, 62S; lane 7, 68S; lane 8, 68R; lane 9, 70S; lane 10, 70R; lane 11 , 72R; lane 12, 
72S; lane 13, 73R; lane 14, 73S; lane 15, no DNA. 
38 
2.3.3 RFLP Analysis ofjlaA 
Primers (Cj 431 and Cj 433) described by Ayling et al., (1996) were initially used for 
amplification of the flaA gene [Table 2.1; Fig 2.2]. A product of the correct size was 
obtained with C. jejuni DNA but no product was obtained with DNA from 20/22 C. 
coli isolates. Varying the PCR conditions did not result in an amplification product. 
This was an unexpected result, as Ayling et al. , (1996) indicated that their primers 
could be applied to C. coli isolates. It should be noted that although a product of the 
correct size was obtained with C. coli NCTCl 1283, using these primers (Fig 2.5), 
amplicons were not obtained with the majority of C. coli isolates. To investigate 
further, the DNA sequences offlaA from C. jejuni (Accession number X57173) and 
C. coli (Accession number M64671) were aligned. A number of mismatches between 
primers and the target sequence were observed, particularly between Cj 433 (Fig 2.4). 
A set of primers (Cc 431 and Cc 433) which bind within the same regions as primer 
Cj 431 and primer Cj 433 (Fig 2.4) was designed specifically for C. coli flaA 
sequences. No PCR product was obtained using primers Cc 431 and Cc 433. As 
heterogeneity of the 3 'end of flaA has been described (Harrington et al., 1997), it is 
possible that there are mismatches between Cc 433 and the target sequence. The 
primer, A2, described by Nachamkin et al., (1993) anneals to sequences located 
approximately 200 bp downstream of the binding site of primer Cc 433 [Fig 2.2]. This 
sequence is in a more conserved region offlaA and is present in C. coli and C. jejuni. 
Thus, primer A2 was used in conjunction with Cc 431 to amplify flaA of C. coli. 
Using these primers, approximately 1,700 bp amplicons were anticipated. Figure 2.5 
shows the amplification products obtained using the different combinations of 
primers. 
Cj 431 5' AAAGGATCCGCGTATTAACACAAATGTTGCA 3' 
I I I I I 111111111111111 
Cc 431 5' CGTATTAACACAAATGTTGC 3' 
Cj 433 5' GATTTGTTATAGCAGTTTCTGCTATATCC 3' 
I I I 1111 
Cc 433 5' CGTGCGCTAGATACTATCTG 3' 
Figure 2.4 Primers specific for C coli flaA. Primers Cj 431 and Cj 433 (Ayling et al., 
1996) were designed for the flaA of C. jejuni (red). Primers Cc 431 and Cc 433 (this study) 
are specific forflaA ofC. coli (blue). 
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2.0kb ~ 
1.5kb ~ 
1.0kb ~ 
1 2 3 4 5 6 7 8 9 10 11 12 
Figure 2.5 Amplicons obtained using different sets of primers. 
Lane 1 - Molecular weight marker 1 kb DNA ladder (Promega). 
Lane 2 - C. jejuni; primers Cj 431 & A2; expected product size approximately 1. 7 kb. 
Lane 3 - C. jejuni; primers Cc 431 & A2; expected product size approximately 1. 7 kb. 
Lane 4- C. coli NCTCl 1283; Cj 431 & A2; expected product size approximately 1.7 kb. 
Lane 5 - C. coli NCTCl 1283; Cc 431 & A2; expected product size approximately 1.7 kb. 
Lane 6 - C. coli NCTCl 1283; Cj 431 & Cj 433; expected product size approximately 1.5 kb. 
Lane 7 - C. coli NCTC 11283; Cc 431 & Cj 433; expected product size approximately 1.5 kb. 
Lane 8 - C. coli sample 62S; Cj 431 & A2; expected product size approximately 1. 7 kb. 
Lane 9 - C. coli sample 62S; Cc 431 & A2; expected product size approximately 1. 7 kb. 
Lane 10 - C. coli sample 6R; Cj 431 & A2; expected product size approximately 1. 7 kb. 
Lane 11 - C. coli sample 6R; Cc 431 & A2; expected product size approximately 1. 7 kb. 
Lane 12 - No DNA. 
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Using primers Cc 431 and A2, amplicons were obtained from 92% (56/61) of the C. 
coli isolates. Representative amplicons of the expected size (1. 7 kb) are shown in 
Figure 2.6. 
2.0 kb __. 
1.t:i kh __. 
Figure 2.6 Amplification products obtained with C. coli DNA. Lane 1, Molecular weight 
marker 1 kb DNA ladder (Promega); lane 2, C. coli NCTC 11283; lane 3, 57R; lane 4, 58R; 
lane 5, 58S; lane 6, 59R; lane 7, 60S; lane 8, 62R; lane 9, 62S; lane 10, 65S; lane 11 , 66R; 
lane 12, 67R; lane 13, 68R; lane 14, 68S; lane 15, 60R; lane 16, no DNA. 
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Following restriction of the jlaA amplicons with Ddel, 14 profiles were obtained. A 
schematic diagram representing all the profiles is shown in Figure 2.7. 
PROFILES 
1 kb 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
-
-
-
- -
-1.0 kb _. 
- -
-
_. 
--0.75 kb 
- -
-
--
- -0.50 kb _. 
- -
- -0.25 kb -
-. 
--- -
--
-- - -
---- - -- ---
-
------ - -
- - -
-
Figure 2.7 A schematic diagram representing all 14 profiles from C. coli isolates. 
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2.3.3.1 C. coli from Pigs on Farm A 
An analysis of the profiles identified 13 distinct profiles in the 55 strains from the pigs 
on farm A (Figs 2.8A, B, C & D; Table 2.4). All except 2 profiles (profiles 2 and 6), 
were observed in both resistant and sensitive strains. Profile 1 (Fig 2.8A lanes 1, 11, 
17) was the commonest profile observed (15 strains). This profile was also exhibited 
by C. coli NCTC 11283 . It is interesting to note that C. coli NCTC 11283 was isolated 
from pig faeces (On, 2001). A number of serotypes were identified within profile 1 
although 7 of the isolates with this profile were non-typeable (Table 2.4). The second 
commonest profile, profile 8 (Fig 2.8A lanes 10, 14), consists of 9 samples, of which 
8 were non-typeable. Profile 6 (Fig 2.8A lanes 8, 18) consists of seven samples and is 
the third largest group. Two points are noteworthy with respect to isolates with this 
profile: They are resistant to ciprofloxacin and nalidixic acid, and they have identical 
serotypes (0:24). The other group (3 isolates) consisting of resistant strains only 
contains profile 2. These strains did not share the same serotypes (Table 2.4). The 
other interesting group of strains, from a typing perspective, have profile 5: 3/3 strains 
are serotype 48 (Table 2.4). In addition, all of the 0:48 strains were resistant to 
ciprofloxacin and nalidixic acid. 
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A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1.0 kb 
0.75 kb 
0.50 kb _. 
0.25 kb _. 
Profile: l 2 3 4 5 4 6 7 8 l l 2 8 5 5 l 6 3 
Serotype: 30 59 5 48 5 24 59 NT NT 34 NT 48 48 59 24 54 
B 
1.0 kb _. 
0.75 kb _. 
0.50 kb _. 
0.25kp _. 
Profile: 
Serotype: 
1 2 3 4 5 6 7 8 9 10 11 12 13 
-
l 3 6 9 11 l 8 1 1 
NT 24 NT 24 NT 34 34 NT 
-
Figure 2.8 flaA profiles among C. coli samples, from farm A, digested with the 
restriction enzyme Ddel. (A) Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); 
lane 2, C. coli NCTC 11283; lane 3, 4R; lane 4, 6R; lane 5, lOR; lane 6, l lR; lane 7, 14R; 
lane 8, 23R; lane 9, 7S; lane 10, 8S; lane 11 , NCTC 11283; lane 12, 12S; lane 13 , 19R; lane 
14, 19S; lane 15, 20R; lane 16, 20S; lane 17, 22S; lane 18, 24R; lane 19, 24S; lane 20, 
Molecular weight marker 1 kb DNA ladder. 
(B) Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); lane 2, C. coli NCTC 
11283 ; lane 3, 26R; lane 4, 38R; lane 5, 40R; lane 6, 43R; lane 7, NCTC 11283; lane 8, 38S; 
lane 9, 39S; lane 10, 46S; lane 11 , 47S; lane 12, Blank; lane 13, Molecular weight marker 1 
kb DNA ladder. 
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1.0 kb 
0.75 kb 
0.50 kb 
0.25 kb 
Profile: 11 68668611 21111 8 
Serotype: 
1.0 kb 
0.75 kb 
0.50 kb 
0.25 kb 
D 
Profile: 
Serotype: 
24 24 NT 24 24 NT 24 5 5 5,30 5 5 24 NT 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
• 
1 1 8 8 9 10 11 1 1 8 l 12 13 
NT NT NT 30 NT NT NT NT NT 34 NT 
Figure 2.8 flaA profiles among C. coli samples, from farm A, digested with the 
restriction enzyme Ddel. (C) Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); 
lane 2, C. coli NCTC 11283 ; lane 3, 53R; lane 4, 54R; lane 5, 55R; lane 6, 57R; lane 7, 59R; 
lane 8, 60R; lane 9, 62R; lane 10, NCTC 11283; lane 11 , 66R; lane 12, 67R; lane 13, 68R; 
lane 14, 70R; lane 15, 71R; lane 16, 72R; lane 17, 73R; lane 18, Molecular weight marker 1 
kb DNA ladder. 
(D) Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); lane 2, C. coli NCTC 
11283; lane 3, 53S; lane 4, 57S; lane 5, 58S; lane 6, 60S; lane 7, 62S; lane 8, 65S; lane 9, 
NCTC 11283; lane 10, 68S; lane 11 , 69S; lane 12, 70S; lane 13, 72S; lane 14, 73S; lane 15, 
Molecular weight marker 1 kb DNA ladder. 
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Table 2.4 flaA profiles and Penner serotypes of C coli isolates from farms A and B. 
flaA Profile Number of Samples per Serotype Number of Resistant (R) and 
Profile Sensitive (S) Isolates 
l 17 NT1 (x7) R=7 
NT S=8 
59 S=2 
24 (x3) 
34 
5,30 
5 (x2) 
54 
2 3 30 R=3 
34 S=O 
5 
3 3 59 R=2 
54 S=l 
NT 
4 3 5 (x2) R=2 
54 S=l 
5 5 48 (x3) R=2 
48 (xl) R=2 
NT S=l 
6 7 24 (x7) R=7 
S=O 
7 2 59 S=l 
39 47 R=l 
8 9 NT (x8) R=3 
34 S=6 
9 2 NT R=l 
30 S=l 
10 l NT s 
11 1 NT s 
12 1 34 s 
13 1 NT s 
14 1 59 R 
1 Non-typeable 
Blue, indicates strains are from farm A; Red, indicates strains are from farm B. 
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A more detailed analysis with respect to the paired resistant and sensitive isolates 
from 15 pigs on farm A shows that amplicons were not obtained from one of each of 
three pairs of isolates (12R, 46R and 58R). The profiles of the remaining 12 pairs 
were different from each other with the exception of 4 pairs highlighted in Table 2.5. 
Both 20R and 20S havejlaA profile 5 (Fig 2.8A lanes 15 & 16) while paired samples 
53R, 53S (Fig 2.8C lane 3; Fig 2.8D lane 3); 68R, 68S (Fig 2.8C lane 13; Fig 2.8D 
lane 10); and 70R, 70S (Fig 2.8C lane 14; Fig 2.8D lane 12) havejlaA profile 1. 
Table 2.5 Serotypes andjlaA profiles of paired resistant and sensitive isolates. 
' .,, . ' ' . ,_ .. ~ ' . . , .... ' , . . ., . ~ - ., . , \ :;· 
' . .. ... '•, , ' 
12R NT1 NIA2 
12S NT 1 
19R 0 :34 2 
19S NT 8 
20S 0 :48 5 
20R 0 :48 5 
24R 0 :24 6 
24S 0 :54 3 
38R 0 :24 6 
38S NT 1 
46S 0 :34 1 
46R 0 :24 NIA 
53S NT 1 
53R 0 :24 1 
57S NT 8 
57R 0 :24 6 
58R 0 :5 ; 0 :24 NIA 
58S NT 8 
60R NT 8 
60S 0 :30 9 
62R 0 :24 6 
62S NT 10 
68S NT 1 
68R 0 :5 ; 0 :30 
70S NT 1 
70R 0 :5 I 
72R 0 :24 1 
72S 0 :34 12 
73R NT 8 
73S NT 13 
1 NT Non-typeable 
2 NI A No amplicon obtained. 
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2.3.3.2 C. coli from Pigs on Farm B 
Profiles observed in strains from pigs on farm A were identified in strains from pigs 
on farm B (Table 2.4; Fig 2.9). Both of the strains with profile 1 were sensitive, the 
remaining strains from farm B were all resistant. Profile 14 (1 strain) is the only 
profile not exhibited in strains from farm A. Two of the remaining strains exhibited 
profile 5. As with 2/3 profile 5 strains from farm A, one of the farm B strains was 
0 :48, and resistant to ciprofloxacin and nalidixic acid. The other could not be 
serotyped. The profile (profile 7) of the third isolate was also identified in one farm A 
strain, however their serotypes were different. In addition, the farm A isolate was 
sensitive whereas the farm B isolate was resistant to these antibiotics. 
1.0 kb 
0.75 kb 
0.50 kb _. 
0.25kb _. 
Profile: 
Sero type: 
l 2 3 4 5 6 7 8 
1 14 7 1 1 5 5 
59 39,47 54 NT 48 NT 
9 
II 
Figure 2.9 jlaA profiles among C. coli samples, from farm B, digested with the 
restriction enzyme Ddel. Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); 
lane 2, C. coli NCTC 11283; lane 3, 2MF2034; lane 4, 3MF2035; lane 5, 5MF2036; lane 6, 
7MF2037; lane 7, 9MF2038; lane 8, 10MF2039; lane 9, Molecular weight marker I kb DNA 
ladder (Promega). 
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2.3.3.3 Absence of Amplicons: An Investigation 
No amplicons were obtained from 5 of the 61 isolates, all from farm A, despite 
modifications to the assay (annealing temperature, primer concentration, MgCb and 
DNA concentration). To investigate further, PCR assays were carried out using each 
of the primers in separate assays. When forward primer, Cc 431, was used a product 
from all except one of the isolates was obtained (Fig 2.10). On the other hand, when 
primer A2, which anneals to the 3 'end of the flaA gene was used, no products were 
obtained, suggesting a lack of complementarity between the primers and the target 
sequence. This was surprising since A2 anneals to the more conserved region offlaA. 
2.0kb _. 
1.5kb _. 
Figure 2.10 PCR assay, using single primers. 
Lane 1 - Molecular weight marker 1 kb DNA ladder (Promega); 
Lane 2 - C. coli NCTC 11283, primers Cc 431 & A2; 
Lane 3 - C. coli sample 46R, primer Cc 431; 
Lane 4 - C. coli sample 46R, primer A2; 
Lane 5 - C. coli sample 12R, primer Cc 431; 
Lane 6- C. coli sample 12R, primer A2; 
Lane 7 - C. coli sample 2R, primer Cc 431; 
Lane 8 - C. coli sample 2R, primer A2; 
Lane 9- C. coli sample 58R, primer A2; 
Lane 10- C. coli sample 58R, primer Cc 431; 
Lane 11 - C. coli sample 42S, primer A2 
Lane 12 - C. coli sample 42S, primer Cc 431 
Lane 13 - no DNA. 
Lane 14-Molecular weight marker 1 kb DNA ladder (Promega). 
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2.4 DISCUSSION 
There have been many typing schemes, both phenotypic and genotypic, used in the 
study of Campylobacter spp. Phenotypic methods include techniques such as 
serotyping (Penner & Hennessy, 1980; Lior et al. , 1982;) which are useful for 
epidemiological purposes, however may lack the necessary discriminatory power 
between strains. Genotypic methods, including PFGE (Yan et al. , 1991 ; Salama et al. , 
1992; Fujita et al. , 1995; Bourke et al. , 1996), RAPD (Williams et al. , 1990; Madden 
et al. , 1996) and flagellin gene typing (Nachamkin et al. 1993), have a higher 
typeability between strains but in some instances these methods maybe too complex 
to perform. Combinations of serotyping and genotyping methods result in a higher 
discriminatory power between strains, and therefore a more complete strain 
identification (Wassenaar & Newell, 2000). In this study, a combination of 
serotyping, andjlaA typing (Nachamkin et al. , 1993; Ayling et al. , 1996) were used to 
type porcine isolates of C. coli. 
Serotyping, based on the Penner & Hennessy scheme (1980), was carried out on the 
61 isolates of C. coli (Table 2.3). Thirty-eight (62%) of the isolates were typeable 
while 23 (38%) were non-typeable. The number of non-typeable isolates is high; 
using the same serotyping scheme, Jacobs-Reitsma et al. (1995) reported that 19% of 
Campylobacter spp. isolates from a Dutch poultry farm were non-typeable. Similarly, 
Frost et al. (1998), reported 12% of C. coli isolates from clinical cases in the UK were 
non-typeable. Using LEP serotyping, McKay et al. (2001) reported that 37% of 
Campylobacter spp. were non-typeable. 
A scatter of serotypes and a number of jlaA profiles were identified in the strains 
typed. Nielsen et al., (1997), showed that 0:30 and 0 :46 were the commonest 
serotypes among porcine C. coli. In this study, 0:24 was the most common serotype 
(11/38 strains) (Table 2.3). Seven of these strains had the samejlaA profile (profile 6) 
(Table 2.4), indicating good correlation between this serotype and.flaA typing, in this 
instance. Three of the 0:24 strains had.flaA profile 1. The remaining strains could not 
be typed. A feature of all serotype 24 strains is their uniform resistance to 
ciprofloxacin and nalidixic acid. The only other serotype consistently associated with 
resistance to ciprofloxacin and nalidixic acid was 0 :5, and as with 0:24 strains, two 
profiles (profiles 1 and 4) were observed in the strains. Whether serotypes 5 and 
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24 are predisposed to developing resistance is not known. Interestingly, one isolate 
(58R) exhibited both these serotypes (5; 24); however, its flaA profile could not be 
determined. The possibility of antigenic shift, associated with changes in antigenic 
specificity related to the O side chains of the LPS molecule has been described (Mills 
et al. , 1991). They showed that C. coli is capable of undergoing genomic re-
arrangements that lead to changes in LPS specificity and structure. The observation 
that most of the flaA profiles contain a variety of serotypes was not surprising; similar 
results were reported from other studies (Alm et al. , 1993; Burnens et al. , 1995; 
Santesteban et al. , 1996), suggesting thatflaA typing is more discriminatory. 
With respect to paired resistant and sensitive isolates from pigs on farm A. Each of 
four (20R/20S; 53S/53R; 68S/68R; 70S/70R) of the 12 pairs had the sameflaA profile 
(Table 2.5). Profile 1 was identified in 3 pairs, while profile 5 was exhibited in 1 pair 
(20R/20S). In addition to having the same flaA profile, the latter pair had identical 
serotypes (0:48).These data suggest that resistant mutants from a previously sensitive 
population have been selected in these pigs. 
Resistant and sensitive strains were isolated from farm B. Both serotype (0:59, 0:54, 
and 0:48) and flaA profiles (profiles 1, 5, and 7) (Table 2.4) observed in resistant 
strains from farm A were exhibited by resistant strains from farm B, suggesting a 
relatedness between some strains from the two farms. As farm B is the supplier of 
pigs to farm A, it is may be that the pigs on farm A were received already colonised 
with resistant strains. On the other hand, may be resistance arose independently on the 
two farms. 
Overall, there was variable relationship between Penner serotype and flaA profile. A 
single profile could consist of up to 6 serotypes (Table 2.4; Profile 1), however in 
general profiles consisted of one, two or three serotypes. Conversely, a single 
serotype comprised a number of flaA profiles. This was not surprising as other studies 
have shown variable correlation between serotyping and flaA typing (Alm et al. , 
1993; Burnens et al. , 1995; Santesteban et al. , 1996). Although studies have 
demonstrated direct correlation between flagellin typing and serotyping), the 
correlations are generally weak (Nachamkin et al. , 1993; Owen et al., 1993b; Burnens 
et al., 1995; Nachamkin et al., 1996). 
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Although significant heterogeneity among the flaA gene of C. jejuni has been shown 
in previous research (Thornton et al. , 1990; Nachamkin et al. , 1993), Thornton et al., 
(1990) suggested that Campylobacter flagellins are more conserved than is indicated 
by the HL serotyping scheme of Lior et al. , (1982). This is contradicted by results 
from Nachamkin et al. (1993), suggesting that at the nucleotide level there is more 
heterogeneity than is suggested by HL serotyping. Results from this study support 
those ofNachamkin et al. , (1993) for the Penner scheme of serotyping. The variety of 
profiles indicates that there is greater heterogeneity within the flaA gene than 
indicated by the Penner scheme. 
Using a variety of primers, amplicons were not obtained with DNA from 5 isolates. 
Significantly, in the cases investigated, this was due to the lack of primer binding to 
the 3 'end of flaA. Heterogeneity of the 3 'end of flaA could explain this result. There is 
strong evidence for intergenomic recombination between flaA genes of different 
strains (Wassenaar et al., 1995; Harrington et al. , 1997). Furthermore, Harrington et 
al. (1997) provided evidence for intragenomic recombination between the flaA and 
flaB genes of individual strains. The frequency of such recombination in natural 
circumstances is unknown but clearly such heterogeneity would disadvantage flaA 
typing. For this reason Newell et al., (2000) has suggested flaA typing needs to be 
supported by additional phenotypic or genotypic methods for accurate analysis. 
Interestingly, C. coli NCTC 11283 isolated in 1970 (On, 2001) exhibited profile 1 
suggestingflaA stability. 
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3.1 INTRODUCTION 
In this study, 57% (35/61) of the C. coli isolates were resistant to ciprofloxacin and 
nalidixic acid, while 43% (26/61) were susceptible. This chapter describes the studies 
carried out to determine the molecular basis of the resistance. 
3.1.1 Treatment 
Diarrhoea resulting from C. jejuni and C. coli is generally a self-limiting disease 
lasting up to 5 days. Infection can persist longer and may develop into severe forms, 
especially in children and immunocompromised patients (Blaser et al., 1979; Blaser et 
al. , 1984). Early treatment with antibiotics is recommended to reduce severity and 
duration of infection. Erythromycin, fluoroquinolones and tetracyclines are the 
antimicrobial agents commonly used to treat severe cases of C. jejuni infection 
(Blaser, 1997; Altkreuse et al., 1999). Fluoroquinolones are often the treatment of 
choice for adults and are also prescribed for prophylactic treatment against traveller's 
diarrhoea (Taylor et al., 1991; Nachamkin, 1993; Piddock, 1995). Fluoroquinolone 
resistance has been described in Campylobacter spp. (Piddock, 1995). 
3.1.2 Fluoroquinolone Resistance 
Fluoroquinolones were introduced in the early 1980s and were hailed with great 
enthusiasm as a new class of antibiotic for antibiotic therapy. Fluoroquinolones are 
active against most major pathogens causing bacterial enteritis, and had good in vitro 
activity against all Campylobacter spp. and against members of the family 
Enterobacteriaceae (Taylor et al., 1985; Wolfson & Hooper, 1989; Bryan et al., 
1990). Besides their potent in vitro activity against susceptible bacteria, 
fluoroquinolones can achieve high concentrations in the gastrointestinal tract (Du 
Pont et al., 1987). Unfortunately, since the late 1980s, resistance to fluoroquinolones 
in campylobacter isolates has been increasing (Piddock, 1995), especially in Europe 
following the introduction of enrofloxacin ( a derivative of ciprofloxacin) into 
veterinary medicine and, less importantly, the use of fluoroquinolones in human 
medicine. 
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Resistance in Campylobacter spp. can arise in vivo, sometimes even after only one or 
two administrations of fluoroquinolones (Adler et al. , 1991 ). The induction of 
fluoroquinolone resistance during antibiotic therapy is recognised and frequently 
reported (Adler et al., 1991 ; Ellis et al. , 1995; Segreti et al. , 1992). Fluoroquinolone 
resistant Campylobacter continues to be a problem (Piddock, 1995), resistance has 
been reported in a number of countries including the UK (Gaunt & Piddock, (1996), 
the USA (Smith et al. , 1999; Zirnstein et al. , 1999), the Netherlands (Koenraad et al. , 
1995), Spain (Saenz et al., 2000), Sweden (Sjogren et al. , 1997), and Thailand 
(Kuschner et al. , 1995). 
3.1.3 Mode of Action of Fluoroquinolones 
Fluoroquinolones, including ciprofloxacin, ofloxacin, and norfloxacin are a subgroup 
of quinolones derived from naladixic acid and possess a fluorine at the C-6 position of 
the quinolone structure. These microbial agents target the type II topoisomerases 
DNA gyrase and topoisomerase IV (Drlica & Zhao, 1997). The enzymes are essential 
for DNA replication, recombination and transcription. Both topoisomerases are 
tetramers composed of two subunits arranged into A2B2 holoenzymes: gyrase is 
GyrA2GyrB2, and topoisomerase IV is ParC2ParE2 (Drlica & Zhao, 1997). DNA 
gyrase catalyses the negative supercoiling of relaxed or positively supercoiled, double 
stranded, covalently closed circular DNA (Gellert et al. , 1977; Maxwell, 1992) while 
topoisomerase IV is involved in separation. Fluoroquinolones form a ternary complex 
with gyrase and the DNA rather than directly binding to the gyrase or DNA (Willmott 
& Maxwell, 1993). The fluoroquinolone-gyrase DNA complex prevents DNA 
replication and transcription resulting in termination of cell growth. Cleavage of 
double stranded DNA follows complex formation resulting in cell death (Drlica & 
Zhao, 1997; Kampranis & Maxwell, 1998). 
3.1.4 Mechanisms of Resistance to Fluoroquinolones 
Mutations in the genes gyrA and/or pare encoding the A subunits of the enzymes are 
the commonest mechanisms observed in clinical isolates of gram-negative bacteria 
(Everett & Piddock, 1997). In E. coli, most mutations resulting in fluoroquinolone 
resistance have been shown to map to a small region termed the quinolone resistance 
determining region (QRDR) near the N terminus of the DNA gyrase GyrA subunit 
between codons 67 and 106 (Yoshida et al., 1990). Similarly, Wang et al. (1993) 
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demonstrated that mutations in the corresponding region of gyrA from C. jejuni, 
specifically at Thr-86, were associated with fluoroquinolone resistance (16-64 µg/ml) . 
In the same study, different mutations (Asp-90 and Ala-70) were also identified but 
these resulted in only modest increase in ciprofloxacin MIC (1 and 4 µg/ml) (Wang et 
al. , 1993). Other studies have identified the same mutation (Thr-86) in humans and 
chicken isolates of C. jejuni (Everett et al., 1995; Ruiz et al., 1998) and in clinical 
isolates with ciprofloxacin MICs of 34-125 µg/ml (Gibreel et al., 1998). In the same 
study a comparison of the QRDR of parC from ciprofloxacin resistant C. jejuni and 
susceptible E. coli identified a mutation leading to the incorporation of arginine 
instead of glutamine at position 139 in ParC of C. jejuni. It was suggested that the 
combination of mutations (gyrA/parC) played a role in the resistance. However, this 
interpretation may be flawed because the same mutation was identified in susceptible 
C. jejuni isolates (Gibreel et al. , 1998). 
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3.2 EXPERIMENTAL PROTOCOL 
3.2.1 Minimum Inhibitory Concentrations 
The minimum inhibitory concentrations (MICs) of ciprofloxacin were carried out on 
all the isolates in this study [Table 2.2]. The MICs of ciprofloxacin were determined 
using E-strips (AB Biodisk, Solna, Sweden) by a medical technologist in the clinical 
microbiology laboratory, Groote Schuur Hospital. The E-test constitutes a predefined 
exponential gradient of antibiotic concentrations immobilised along a rectangular 
plastic test strip. The strip is applied to the surface of an agar plate inoculated with the 
isolate to be tested. Following incubation overnight, a drop shaped zone of inhibition 
is seen. The edge of the zone intersects the graded test strip at the inhibitory 
concentration of the antibiotic. The MIC is read where the inhibition ellipse intersects 
the scale on the strip. The MIC is read as the lowest concentration of antibiotic 
required to cause a marked decrease in growth. 
3.2.2 Amplification of the gyrA Gene 
PCR [ section 2.2.6 and Fig 2.1] was utilised for the amplification of the QRDR of the 
gyrA gene. Chromosomal DNA was purified as stipulated [section 2.2.2] and diluted 
to approximately 200 ng/µl for the assays. 
3.2.2.1 Primers 
Primers used for the amplification are shown in Table 3.1. Primer sets were 
synthesised by GIBCO BRL, Custom Primer services (Life Technologies). Initially, 
the degenerate primer set, GyrAl and GyrA2, based on the nucleotide sequence of C. 
jejuni (Wang et al. , 1993), was used for the amplification of a 449 bp DNA fragment 
encoding the amino-terminal of GyrA. During the course of these studies, primers 
specific for amplification of the QRDR of C. coli (505 bp product) were published 
(Zimstein et al., 2000) and these were used in later experiments. Figure 3.1 is a 
schematic diagram of the gyrA gene showing the annealing sites of the primer sets. 
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Table 3.1 Primers used in the amplification of QRDR of the gyrA gene. 
I', imt· r '\.11111· '-t'tjlll' lltt· (~·lo.\' 11 n, n ·rl 11111 
GyrAl GTI AGI GAT GGI ITI AAG CCI GTI CAT Forward 
GyrA2 GTG IGGIGGTAT GIT IGT IGC CAT Reverse 
GZgyrACcoli3F TATGAGCGTTATTATCGGTC Forward 
GZgyrACcoli4R GTC CAT CTA CAA GCT CGT TA Reverse 
1 Where is I is deoxyinosine 
._ GyrA2 GyrAl ~ 
GZJ011'ACcoli3F ~ ._ GZJ011'ACcoli4R 
5' 
Figure 3.1 A schematic representation of the PCR primer binding sites. 
lklt-11·11n· 
Wang et al., 
(1993) 
Wang et al., 
(1993) 
Zirnstein et al. , 
(2000) 
Zirnstein et al., 
(2000) 
GyrAl, GyrA2; and GZgyrACcoli3F, GZgyrACcoli4R; were designed to amplify the QRDRs of C. 
Jejuni and C. coli respectively (Wang et al., 1993; Zirnstein et al., 2000). 
3.2.2.2 PCR Assay Conditions 
Amplification using GyrAl and GyrA2 was carried out according to Wang et al., 
(1993) using a modified protocol: Initial denaturation was performed at 95°C for 5 
minutes, followed by 30 cycles of 94°C for 1 minute, 54°C for 1 minute, 72°C for 1 
minute. A final extension took place at 72°C for 7 minutes. 
PCR cycling conditions using GZgyrACcoli3F and GZgyrACcoli4R were as follows: 
initial denaturation at 94°C for 3 minutes, followed by 30 cycles of94°C for 1 minute, 
50°C for 1 minute and 72°C for 1 minute, with a final step at 72°C for 5 minutes 
(Zirnstein et al., 1999). All PCR thermocycling reactions were carried out in a Perkin 
Elmer GeneAmp PCR System 2400. 
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3' 
When necessary, PCR products were purified, following agarose gel electrophoresis, 
using the phenol-squeeze method [section 3.2.4]. 
3.2.3 Amplification of pare 
3.2.3.1 Primers 
Primers used for the amplification of the QRDRparC are shown in Table 3.2 . Primer 
sets were synthesised by GIBCO BRL, Custom Primer services (Life Technologies). 
Primers are based on the QRDR parC of C. jejuni and their binding sites are shown in 
Figure 3.2. 
Table 3.2 Primers used for parC amplification. 
1'1 lllll"I' 01 it·111.11i1111 '-t"(llll'lll' l' (:-· ,.1 .. , lfrlt'l l ' lll l' 
\ ,lllll' ( I 11n1anl l{t·1t· rw1 
Pl Forward TGGGATCCAAACCTGTfCAGCGCCGCA Gibreel et 
TT al. , (1998) 
P2 Reverse CGGAATfCGTGGTGCCGTfAAGCAAA Gibreel et 
al., (1998) 
CjparCR2 Reverse ATATCCAGCAGCTGATCG This study 
CjparCF2 Forward GTATGCGATGTCTGAACTGG This study 
CiparCR6 Reverse GCCACTfCACGCAGGTfATG This study 
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Pl CjparCF2 
140 AAACCTGTfCAGCGCCGCATfGTGTATGCGATGTCTGAACTGGGCCTGAATGCCAGCGCC 
200AAATTfAAAAAATCGGCCCGTACCGTCGGTGACGTACTGGGTAAATACCATCCGCACGGC 
260GATAGCGCCTGTfATGAAGCGATGGTCCTGATGGCGCAACCGTfCTCTfACCGTfATCCG 
320CTGGTfGATGGTCAGGGGAACTGGCGGCGATCGCCGGACGATCCCAAATCGTfCGCGGCA 
380ATGCGTfACACCGAATCCCGGTfGTCGAAATATfCCGAGCTGCTATfGAGCGAGCTGGGG 
440CGGGGGACGGCTGACTGGGTGCCAAACTfCGACGGCACTTfGCAGGAGCCGAAAATGCTA 
P2 
500CCTGCCCGTCTGCCAAACATfTfGCTfAACGGCACCACCGGTATfGCCGTCGGCATGGCG 
CjparCR6 
560ACCGATATfCCACCGCATAACCTGCGTGAAGTGGCTCAGGCGGCAATCGCATfAATCGAC 
CjparCR2 
620CAGCCGAGAACCACGCTCGATCAGCTGCTGGATATCGTGCAGGGGCCGGATfATCCGACT 
680GAAGCTGAAATfATCACTfCTCGAGCCGAGATCCGTAAAATGTATGAGAAAGGACGTGGT 
740TCAGTGCGTATGCGCGCGGTGTGGAAGAAAGAAGATGGCGCGGTGGTfATCAGCGCATfG 
800CCACAACAGGTTfCAGGTGCGCGCGTACTGGAGCAAATfGCTGCGCAAATGCGCAACAAT 
860AATGTGCCGATGGTCGACGATCTGCGCGATGAATCTGACCACGAGAAACCGACCCGCCTG 
Figure 3.2 QRDR (bases 140-919) of C jejuni parC (accession number Y18300). Arrows 
indicate the primers used in PCR assays. 
3.2.3.2 PCR Assay Conditions 
Initially, amplification of the QRDR of pa,.C was carried out according to the method 
of Gibreel et al., (1998): Initial denaturation was performed at 94°C for 3 minutes 
followed by 30 cycles of 94 °C for 1 minute, 58°C for 1 minute and 72°C for 1 
minute, with a final step at 72°C for 5 minutes. Optimisation/modification of the 
assay included the following: variation of annealing temperature ( 40°C to 60°C), 
MgCh concentration and primer concentration. 
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3.2.4 DNA Purification 
DNA purification was based on the phenol-squeeze method of Sambrook et al., 
(1989). PCR products were electrophoresed [section 2.2.4] and the band of interest 
was excised from the agarose gel. The agarose slice was finely chopped up, and 
placed in an Eppendorf tube. An equal volume of phenol (Appendix A) was added 
and the mixture was placed at -70°C for 10 minutes. The solution was centrifuged at 
14,000 rpm for 10 minutes followed by the removal of the supernatant. An equal 
volume of chloroform-isoamyl (Appendix A) was added to the supemantant to 
remove any residual phenol and agarose. Centrifugation was carried out and the 
previous step was repeated. The DNA was precipitated by the addition of 1/10 volume 
of 3M sodium acetate (NaAC) pH 5.2 (Appendix A) and 3x volumes of 100% ethanol 
(EtOH). The DNA was pelleted by centrifugation at 14,000 rpm for 10 minute. The 
resulting DNA pellet was washed twice with 70% EtOH, dried and resuspended in 
25µ1 of dH20. DNA concentration was determined as in section 2.2.3. 
3.2.5 Cloning 
To facilitate characterisation and to provide glycerol stocks (30% v/v, 70% 2x YT), 
selected PCR products were cloned and the recombinant plasmids were introduced 
into E. coli by transformation. Circular plasmid vectors were cleaved with a 
restriction endonuclease leaving the ends free to ligate with the appropriate ends of 
DNA to be cloned (insert), thereby constructing a recombinant plasmid. Recombinant 
plasmids were introduced into bacterial cells, which had been made competent for the 
uptake of DNA. Recombinants containing the DNA of interest were characterised. 
3.2.5.1 Preparation of Vector DNA (pUC19) 
To obtain blunt-ends, the vector, pUC19 was digested (within the multiple cloning 
site (Appendix C)) with 20U of Smal (CCCtGGG) (Boehringer Mannheim; 
Mannheim, Germany) at 37°C for 2 hours, in the reaction conditions specified by the 
manufacturers. The linearised plasmid was visualised following agarose gel 
electrophoresis [ section 2.2.4] and purified [ section 3 .2.4]. 
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3.2.5.2 Preparation of Insert DNA 
The PCR products were purified [section 3.2.4] and blunted using a DNA blunting kit 
(Amersham International, Buckinghamshire UK) to remove any dATP residues 
incorporated at the 3' end of the amplified product due to the template-independent 
terminal transferase activity of Taq DNA polymerase. Following the removal of the 
overlaps by the 3 ' -5 ' activity of the T4 DNA polymerase, supplied with the blunting 
kit, the DNA mixture was placed on ice in preparation for the ligation reaction. 
3.2.5.3 Ligation Reaction 
Ligation was carried out according to the protocol supplied with the DNA blunting 
kit. Ligase and reaction buffer (supplied with the kit) were added to approximately 
500-800 ng of blunted insert and 100 ng of Smal-digested vector. Ligation took place 
at l 6°C for approximately 8 hours. 
3.2.5.4 Preparation of Competent Cells 
The CaCh shock procedure of Dagert and Ehrlich (1979) was used to make E. coli 
LKl 11 cells competent for the uptake of DNA. A volume of 5 ml of 2x YT broth 
(Appendix A) was inoculated with E. coli LKl 11 and incubated with shaking at 37°C 
0/N. Following incubation, the culture was diluted 1/100 in 100ml 2x YT broth. The 
diluted culture was propagated to early log phase corresponding to an OD600 of 0.2-
0.4. The cells were harvested by centrifugation ( 4000-5000 rpm) for 5 minutes in a 
Beckman J2-21 centrifuge with a JA-10 rotor at 4°C. The cells were gently 
resuspended in Yi culture volume of O. lM ice-cold CaCh. The cells were kept on ice 
for 2 hours and then collected as described previously, and resuspended in 1/10 
culture volume O.lM CaCh, inducing the transient state of competence. Ice-cold 
sterile glycerol was added to a final concentration of 10% (v/v) to allow for indefinite 
storage of cell. Aliquots of competent cells were stored at -70°C. 
3.2.5.5 Transformation 
The ligation mix (5 µl) was added to competent E. coli LKl 11 (100 µl) and placed on 
ice for 30 minutes to facilitate DNA binding to the bacterial cells. A heat shock was 
applied at 42°C for 2 minutes to facilitate uptake of DNA by the cell. To encourage 
expression of the ampicillin resistance gene carried by pUC19 (Appendix C), 0.9 ml 
of 2x YT broth was added to the transformed cells followed by incubation for 1 hour 
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at 37°C. The expression mix (200µ1) was plated onto 2x YT agar plates containing 1 
ml X-gal (5-bromo-4-chloro-P-D-galactoside, 40 mg/ml, Appendix A), 0.1 ml of 
IPTG (Isopropyl-P-D-thio-galactopyranoside, 200 mg/ml, Appendix A), 0.2 ml of 
ampicillin (100 mg/ml, Appendix A) per 200 ml of 2X YT agar (Appendix A). The 
plates were inverted and incubated overnight at 37°C. Cells used were shown to have 
a transformation efficiency of 1.6 x 106. 
3.2.5.6 Screening of E.coli LKlll Containing Recombinant Plasmids 
Selection of recombinants took place on two levels. Firstly, ampicillin was used to 
select for cells carrying pUC 19, which encodes ampicillin resistance. The second 
level of selection is based on the presence or absence of a functional p-galactosidase 
gene. The lacZ gene on pUC19 encodes the amino terminus of the p-galactosidase 
(the a fragment), while E. coli LKl 11 contains the carboxyl terminus of the P-
galactosidase (the p fragment) . Disruption of the lacZ gene as a result of ligation of 
insert DNA into the multiple cloning site (MCS) within the lacZ gene interrupts 
production of the a fragment. It follows that a complementation cannot take place 
and that active p-galactosidase is not present within the cell. The presence of P-
galactosidase is detected by adding X-gal and IPTG to the nutrient agar. IPTG 
induces lacZ production, and X-gal, a substrate for p-galactosidase, is cleaved 
producing a blue colony. In the absence of p-galactosidase, X-gal is not cleaved and 
the colonies appear white, suggesting that the cells contain a recombinant plasmid. On 
the other hand, blue colonies indicate that the bacterial cells contain vector only 
(Sambrook et al. , 1989). 
3.2.5. 7 Small-Scale Plasmid Preparation 
Small-scale plasmid preparations were performed using the method based on Ish-
Horowicz & Burke (1981). A 5ml 2x YT broth (ampicillin selection at 100 µg/ml) 
was inoculated with a single possible recombinant colony. The inoculated broth was 
incubated at 37°C with shaking for 16 hours. The cells were harvested by 
centrifugation at 14,000 rpm for 15 minutes and resuspended in 0.2 ml of glucose/ 
Tris-Cl/EDTA solution I (Appendix A) to create spheroplasts. The cells were lysed 
with SDS, and the resulting DNA was denatured with NaOH (Solution II, Appendix 
A). Selective renaturation of plasmid DNA was facilitated by the addition of 3M 
potassium acetate/glacial acetic acid solution III (Appendix A) at 4°C for 5 minutes. 
The white flocculate containing cellular debris and chromosomal DNA was removed 
by centrifugation. The supernatant was recovered following centrifugation and 
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isopropanol (0.6 volume) was added to precipitate the DNA. The DNA was pelleted, 
washed in 80% ethanol and dissolved in 50 µl of dH20. 
3.2.6 DNA Sequencing 
DNA sequencing was carried out using Automated sequencing (Pharmacia Biotech 
AB S-751 82 Uppsala Sweden) in the Department of Molecular Biology, University 
of Cape Town. 
3.2.6.1 Sequence Analysis 
Sequence similarity searches for nucleic acids was carried out against existing 
nucleotide and databases using the Basic Local Alignment Search Tool, Blast 
(Altschul et al. , 1990); at the National Centre for Biotechnology Information (NCBI), 
National Institute of Health. DNA sequences of interest were analysed by DNAMAN 
version 4.0 (Lynnon Biosoft) computer analysis software for nucleic acid and amino 
acid sequences. 
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3.3 RESULTS 
3.3.1 Antimicrobial Susceptibility 
The MICs of ciprofloxacin were determined for all C. coli isolates using E-strips and 
are shown in Table 3.3. The lowest MIC observed is 0.016 µg/ml and the highest 
MIC, ~32 µg/ml. MIC values for ciprofloxacin can be defined as: sensitive ~ 1 µg/ml; 
intermediate between 1 and 4 µg/ml; and resistant~ 4 µg/ml (NCCLS, 1998b ). 
Table 3.3 Ciprofloxacin MICs of C. coli isolates. 
Sample Antibiotic Resistance (S or R) 1 Ciprofloxacin MIC 
Naladixic Acid Ciprofloxacin (µg/ml) 
Farm A: 
2R R R >32 
4R R R >32 
6R R R >32 
7S s s 0.064 
8S s s 0.25 
IOR R R 32 
l lR R R 4 
14R R R >32 
22S s s 0.125 
23R R R 32 
26R R R >32 
39S s s 0.064 
40R R R >32 
42S s s 0.064 
43R R R >32 
47S s s 0.064 
49S s s 0.125 
54R R R 12 
55R R R 16 
59R R R >32 
65S s s 0.064 
66R R R >32 
67R R R >32 
69S s s 0.125 
71R R R >32 
12S s s 0.5 
12R R R >32 
19S s s 0.032 
19R R R >32 
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20S s s 0.125 
20R R R ~32 
24S s s 0.25 
24R R R ~32 
38S s s 0.064 
38R R R ~32 
46S s s 0.064 
46R R R ~32 
53S s s 0.032 
53R R R ~32 
57S s s 0.125 
57R R R 24 
58S s s 0.032 
58R R R ~32 
60S s s 0.016 
60R R R 8 
62S s s 0.032 
62R R R ~32 
68S s s 0.064 
68R R R ~32 
70S s s 0.125 
70R R R ~32 
72S s s 0.064 
72R R R ~32 
73S s s 0.064 
73R R R 2 
FarmB: 
2MF2034 R R ~32 
3MF2035 R R ~32 
5MF2036 s s 0.25 
7MF2037 s s 0.032 
9MF2038 R R 4 
10MF2039 R R 4 
1 Antibiotic Resistance: disc susceptibility testing, sensitive (S) or resistant (R) 
The paired sensitive and resistant isolates from the same pigs are shown between the two, thick black 
lines. 
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3.3.2 Amplification of gyrA Using Primers GyrAl and GyrA2 
Mutations in gyrA associated with fluoroquinolone resistance in C. jejuni have been 
described (Wang et al. , 1993; Everett et al. , 1995; Ruiz et al. , 1998). Although 
fluoroquinolone resistant C. coli have been described, studies on the molecular basis 
of this resistance were published (Zirnstein et al., 2000) after this study commenced. 
Thus, in the first instance, degenerate primers (GyrAl and GyrA2), which have been 
used to amplify the QRDR gyrA gene of C. jejuni UA580 and C. fetus subsp. f etus 
(Wang et al. , 1993; Taylor & Chau, 1997), were used in PCR assays to amplify the 
corresponding region in C. coli [section 3.2.2.2]. A product of the expected size (449 
bp) was obtained for C. jejuni but no product was obtained for 77% (10/13) of the C. 
coli samples tested. Moreover, when a product of the expected size was amplified, an 
additional larger product was obtained. Representative products obtained using 
primers GyrAl and GyrA2 are shown in Figure 3.3. This data suggested mismatches 
between primer(s) and the target sequence, preventing amplification. To obtain DNA 
sequencing data of the QRDR of gyrA of C. coli, an amplicon of the correct size (449 
bp) was excised from the gel and DNA was purified [section 3.2.4] and subsequently 
sequenced directly. As unsatisfactory DNA sequencing was obtained, a representative 
amplicon was cloned and sequenced [sections 3.2.5 and 3.2.6]. 
1 2 3 
0.50kb __. 
0.25 kb __. 
4 5 6 7 
Expected size 
product 
Figure 3.3 Amplification of the QRDR of gyrA of C. coli isolates using GyrAl and 
GyrA2 (Chau & Taylor (1997). Lanes 1 and 7 Molecular weight marker 1 kb DNA ladder 
(Promega); lane 2, C. jejuni; lane 3, 6R; lane 4, 7S; lane 5, 1 OMF2039; lane 6, No DNA. 
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3.3.3 Cloning PCR Products 
Amplification products from one of the strains (IOMF2039) were cloned into pUC19 
[section 3.2.5]. Following transformation [section 3.2.5.5] more than 1000 white, 
ampicillin resistant colonies were obtained, suggesting that pUCI 9 had been taken up 
by E. coli and that the lacZ gene had been interrupted, thereby preventing a-
complementation. Small-scale plasmid preparation [section 3.2.5.7] was carried out 
on 25 white colonies. Following digestion with EcoRI and BamHI to release the 
insert, the fragments were separated by agarose gel electrophoresis [ section 2.2.4]. As 
shown in Figure 3.4, only 2 of the putative recombinants contained a 449 bp insert. 
The remaining white colonies probably contain pUC19 which has a point mutation in 
the MCS, disrupting a-complementation. One recombinant containing an insert was 
selected: DNA was extracted [section 3.2.5.7] and submitted for sequencing [section 
3.2.6]. 
.__ Insert 
Figure 3.4 Analysis of putative recombinant plamids following restriction endonuclease 
digestion with EcoRI and Bamm. Lanes 1 and 27, Molecular weight marker 1 kb DNA 
ladder (Promega); lanes 2-14 and 16-25, vector (2, 686 bp) DNA; lanes 15 and 26, vector 
DNA and 10MF2039 insert (449 bp). 
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3.3.3.1 Sequence Analysis of QRDR of gyrA of Sample 10MF2039 
The nucleotide sequence of the amplified QRDR of C. coli gyrA MF2039 was smaller 
(444 bp) than that observed by Taylor & Chau, (1997) for C. fetus subsp.fetus (449 
bp), using the primers GyrAl and GyrA2. The nucleotide sequence was aligned with 
the corresponding region of gyrA from C. jejuni (accession number L04566). An 
analysis of the data shows a 77% DNA similarity (Figure 3.5). 
407 AGAGATGGTTTAAAGCCTGTTCATAGAAGAATTTTATATGCTATGCAAAATGATGAGGCA 
11 11111 11 11111 11 1111 111111 I 111111111 I 11 11 I I 
AGGGATGGGTTGAAGCCGGTGC~ AAAAGAATACTTTATGCTATGAATGATCTTGGCGTA 
GyrAl 
467 AAAAGTAGAACAGATTTTGTCAAATCAGCCCGTATAGTGGGTGCTGTTATAGGTCGTTAT 
11111111 I I I 11111 11 11111111 11 I 111111 111 111 
GGAAGTAGAAGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTAT 
527 CACCCACATGGAGATACAGCAGTTTATGATGCTTTGGTTAGAATGGCTCAAGATTTTTCT 
11 111 1111 1111 11 11111 11111 11 11 11111111 11111111 111 
CATCCA . ATGGCGATATTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCT 
587 ATGAGATATCCAAGTATTACAGGACAAGGCAACTTTGGATCTATAGATGGTGATAGTGCC 
111 I 11111111111 11111111 11111111 11111 111111111 I 11 
ATGCGTTATCCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCT 
647 GCTGCGATGCGTTATACTGAAGCAAAAATGAGTAAACTTTCTCATGAGCTTTTAAAAGAT 
11111 111111111111111 I I I 11111 I I I I 111111111 111 
GCTGCAATGCGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGAT 
707 ATAGATAAAGATACGGTCGATTTTGTTCCAAATTATGATGGTTCAGAAAGCGAACCTGAT 
I I 111111111111111 11111111111111 11 1111 111 11 11 11 111 
ATAGATAAAGATACGGTAGATTTTGTTCCAAACTACGATGATTCTATGAGTGAGCCCGAT 
767 GTTTTACCTTCTAGGGTTCCAAATTTATTATTAAATGGTTCAAGTGGTATAGCTGTAGGT 
111111111 1111111 11111111111111111 I I I 11 11111111 111111111 
GTTTTACCTGCTAGGGTGCCAAATTTATTATTAAATGGCTCTAGTGGTATTGCTGTAGGT 
827 ATGGCGACAAACATCCCACCT 
11111 111 111 11 
ATGGCACCAACATACCCCCCA 
1111!1 GyrA2 
Figure 3.5 Alignment of the QRDR gyrA of sample 10MF2039 and the corresponding region of 
gyrA of C. jejuni (accession number AF092101). The top sequence is C. jejuni and the bottom 
sequence is C. coli (IOMF2039). The numbering indicates the nucleotide position within the gyrA gene 
of C. jejuni. Primer sites for GyrAI and GyrA2 are shown by arrows indicating the direction of the 
oligonucleotide. 
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A comparison of the nucleotide sequences of the primers and their target sequences 
identified a number of mismatches, particularly between GyrA2 and its target (Fig 
3.6) 
GyrAl 
5'-GTIAGIGATGGITTIAAGCCIGTICAT-3' 
II 11 111 11 I I I 11 11 11 I 11 
3 1 - CACTCCCTACCCAACTTCGGCCACGTA-S' 
GyrA2 
5'-GTGIGGIGGTATGTTIGTIGCCAT-3' 
11 11111111 11 I 
3'- CACCCCCCATACAACCACGGTAT-5' 
Figure 3.6 Alignment of primers, GyrAl and GyrA2, to primer binding region of C coli 
10MF2039. Primer sequence is on the top line (red), bottom line (blue) is the corresponding binding 
region of 10MF2039. 
These mismatches, particularly those in GyrA2, could account for the absence of 
amplicons. It has been suggested that 3-5 mismatches at 3' -ends will affect extension 
of the primer (Rolfs et al., 1992). 
Subsequent to obtaining this data, Zirnstein et al. , (2000) published sequences of 
primers that they had used to amplify QRDRs of fluoroquinolone resistant C. coli. 
Primers described by Zirnstein et al. , (2000) were used in further studies. 
3.3.4 Amplification of gyrA Using Primers GZgyrACcoli3F and 
GZgyrACcoli4R 
For this part of the study, samples were selected that represented a distribution of 
MICs. The samples used are shown in Table 3.4. Using the primers (GZgyrACcoli3F 
and GZgyrACcoli3F) described by Zirnstein et al., (2000) a product of 505 bp was 
expected. No amplification product was obtained from C. Jejuni DNA. However, 
products of the expected size were obtained with the DNA from the 7 isolates, 
including C. coli NCTC 11283 tested (Fig 3.7). The PCR products obtained from the 
pig isolates were purified [section 3.2.4] and sequenced directly [section 3.2.6]. 
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Table 3.4 C coli isolates, and their corresponding ciprofloxacin MICs, used in the 
QRDR gyrA PCR assays. 
Sample Ciprofloxacin Resistance Ciprofloxacin MIC (µg/ml) 
NCTC 11283 Sensitive 0.032 
19S Sensitive 0.032 
53S Sensitive 0.032 
73R Resistant (Intermediate) 2 
9MF2038 Resistant 4 
19R Resistant ~32 
20R Resistant ~32 
1 2 5 6 7 8 9 
0.75kb __. 
Figure 3.7 Amplification products obtained using GZgyrACcoli3F and GZgyrACcoli4R. 
Lane 1, Molecular weight marker 1 kb DNA ladder (Promega); lane 2, C. coli NCTC 11283; 
lane 3, C. jejuni; lane 4, 19R; lane 5, 19S; lane 6, 20R; lane 7, 53S; lane 8, 73R; lane 9, 
9MF2038. 
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Nucleotide sequence data of the amplicons obtained from the isolates were aligned to 
each other, and to C. coli sequences in Gen Bank (Fig 3.8). Analysis of this data 
identified cytosine and thymine residues at base 260 in the sensitive and resistant 
strains, respectively. The presence of thymine instead of cytosine results in the 
incorporation of isoleucine rather than threonine at codon 86. One other difference 
can be seen at position 300. The sequences C. coli NCTC 11283 (sensitive) and C. 
coli 20R contain a thymine at base 300, whereas cytosine is in the corresponding 
position in the remaining sequences. As this does not result in an amino acid change, 
the mutation is silent. 
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TTAAAGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
----------------------------------------------------
-------- 192 
TTAAAGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
TTAAAGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
TTAAAGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
------------------------CTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
---- AGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 192 
------------------------------------------------GTAGGAAGTAGA 192 
TTAAAGCCTGTTCACAGAAGAATACTTTATGCTATGAATGATCTTGGCGTAGGAAGTAGA 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
-GTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
AGTGCATATAAAAAATCTGCTCGTATAGTAGGGGATGTTATCGGTAAGTATCATCCACAT 252 
gtgcatataaaaaatctgctcgtatagtaggggatgttatcggtaagtatcatccacat 
GGCGATACTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTTTCTATGCGTTAT 312 
GGCGATACTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTTTCTATGCGTTAT 312 
GGCGATACTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTTTCTATGCGTTAT 312 
GGCGATACTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCTATGCGTTAT 312 
GGCGATACTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCTATGCGTTAT 312 
GGCGATATTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCTATGCGTTAT 312 
GGCGATATTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCTATGCGTTAT 312 
GGCGATATTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTCTCTATGCGTTAT 312 
GGCGATATTGCTGTTTACGATGCCTTAGTAAGAATGGCACAAGATTTTTCTATGCGTTAT 312 
ggcgata tgctgtttacgatgccttagtaagaatggcacaagattt tctatgcgttat 
86 99 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCGATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
CCAAGTATCGATGGACAAGGAAACTTTGGTTCTATCGATGGTGATGGCGCTGCTGCAATG 372 
ccaagtatcgatggacaaggaaactttggttctatcgatggtgatggcgctgctgc atg 
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
CG--------------------------------------------------------
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
CGTTATACTGAAGCTAGAATGACAATTT------------------------------
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTT----------------
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
CGTTATACTGAAGCTAGAATGACAATTTTAGCAGAAGAGCTTTTACGCGATATAGATA 
430 
430 
430 
430 
430 
430 
430 
430 
430 
Consensus cg 
Figure 3.8 Nucleotide sequence alignment of partial gyrA gene sequences of C coli 
isolates from this study and C coli isolates in the GenBank database. The sequences of C. 
coli ATCC 33559 (accession number AF092101 , Zimstein et al., (2000)), C. coli NCTC 
11366 (accession number U63413) were compared to QRDR gyrA of C. coli NCTC 11283 
(this study), and C. coli isolates l 9S (MIC=0.032), 53S (MIC=0.032), 73R (MIC=2), 
9MF2038 (MIC=4), 19R (MIC~32), 20R (MIC~32) this study. The consensus sequence is 
shown below. Red indicates codon 86 given in bold; blue indicates codon 99 given in bold. 
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3.3.5 Amplification of the QRDR pare 
The single mutation of threonine to isoleucine at codon 86 in the GyrA protein may 
not be the whole explanation for the range of ciprofloxacin susceptibilities (Table 
3.4). As high-level resistance (MIC of 125 µg/mL) has been shown to be associated 
with mutations in gyrA and pare in other organisms (Vila et al. , 1996; Pan & Fisher, 
1999; Bush & Goldschmidt, 2000), the pare of resistant C. coli isolates was 
amplified. 
Using the primers (Pl and P2) and assay conditions defined by Gibreel et al. , (1998) 
for the amplification of the pare QRDR of C. jejuni, no products were obtained with 
DNA from C. jejuni and C. coli. 
In order to optimise the assay, numerous modifications were carried out: 
3.3.5.1 Primers Titration 
Using the primers at 0.1 µm, 0.5 µm , 1 µm and 1.5 µm , and the same conditions used 
earlier, no QRDR of pare was obtained from C. jejuni or C. coli DNA. 
3.3.5.2 MgCh Titration 
Magnesium chloride was titrated across the following concentrations: 1 mM, 1.5 mM, 
2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM and 5 mM. No product was obtained with the 
DNA from C. j ejuni and C. coli. At 5mM MgCb and 1.5 µm primer, a product of the 
expected size was amplified, purified and sequenced. A comparison of the DNA 
sequence data with sequences in the data bank showed that it was similar to sequences 
in eampylobacter but not related to parC. 
3.3.5.3 DNA Titration 
DNA titration was carried out with the following concentrations: 100 ng, 200 ng, 300 
ng, 400 ng, 800 ng and 1000 ng, using the conditions defined by Gibreel et al. , 
(1998). No product was obtained from C. jejuni and C. coli DNA. 
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3.3.5.4 Variation of Annealing Temperature 
Annealing temperature was varied from 60°C-40°C using conditions specified by 
Gibreel et al. , (1998). No product was obtained from C. jejuni and C. coli DNA. 
3.3.5.5 Design of New Primers 
As a last resort, different primers (CjparCR2; CjparCF2 & CjparCR.6) were designed 
based on the nucleotide sequence of the parC from C. j ejuni (accession number 
Yl 8300) [Table 3 .2; Fig 3 .2]. 
Using primers, Pl and CjparCR2, and the previous parameters described, no product 
was obtained with DNA from C. jejuni and C. coli. 
Primer set, CjparCF2 and CjparCR.6, were designed for the amplification of a 432 bp 
product. Using previously described conditions, no PCR product was obtained from 
C. jejuni DNA. A faint product of the expected size was observed from C. coli sample 
19S: an agarose/DNA plug was taken and used as template in re-amplification. The 
product obtained was purified and sequenced. Once again, the DNA sequencing data 
showed that it was not related to parC. 
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3.4 DISCUSSION 
There is cause for concern over the increasing number of Campylobacter isolates 
resistant to fluoroquinolones worldwide, following the introduction of 
fluoroquinolones into veterinary medicine (Endtz et al. , 1991). Fluoroquinolones are 
used for treatment of Campylobacter infections, thus increased resistance bears on the 
effectiveness of treatment for campylobacteriosis (Smith et al. , 1999). As pigs are a 
food source, they may be a source of resistant strains in humans. In this study, 57% 
(35/61) of the C. coli isolates were resistant to ciprofloxacin and nalidixic acid. In 
another study, 100% of C. coli isolates have been shown to be resistant to 
ciprofloxacin and nalidixic acid (Saenz et al., 2000). 
A single Thr-86 to Ile change was identified in the GyrA proteins in the 4 resistant C. 
coli isolates studied. The GyrA protein for the sensitive strains did not contain this 
mutation, suggesting that the Thr-86 to Ile substitution is responsible for the increased 
resistance to fluoroquinolone antibiotics. This study supports recent work by Zimstein 
et al. (2000) who also examined the gyrA QRDR of C. coli isolates and found that all 
ciprofloxacin resistant C. coli isolates had a Thr-86 to Ile mutation. Other studies on 
the GyrA protein of C. jejuni have shown that fluoroquinolone resistance is associated 
with a Thr-86 to Ile mutation in the GyrA protein (Wang et al., 1993; Charvalos et al. , 
1996; Gaunt & Piddock, 1996; Gibreel et al. , 1998; Ruiz et al. , 1998). Additional 
mutations in the gyrA of C. jejuni have been described by Wang et al. (1993). An 
Asp-90 to Asn and Ala-70 to Thr in two separate mutants resulted in moderate 
increases in the ciprofloxacin MIC: 4 µg/ml and 1 µg/ml , respectively. 
In several other bacteria, mutations associated with quinolone resistance have been 
identified in both gyrA and gyrB genes. In E. coli, several mutations have been 
identified in the gyrA gene (Hallet & Maxwell, 1991 ; Vila et al. , 1994). However, it is 
the Thr-86 to Ile equivalent mutation in E. coli GyrA (Ser-83 to Ala) that is primarily 
responsible for fluoroquinolone resistance in E. coli (Hallet & Maxwell, 1991). 
Similar mutations have also been identified in quinolone resistant isolates of 
Pseudomonas aeruginosa (Kureishi et al. , 1994), Staphylococcus aureus (Sreedharan 
et al. , 1991 ; Goswitz et al., 1992) and Acinetobacter baumannii (Vila et al., 1995). 
However, in gram positive bacteria, such as Staphylococcus aureus and Streptococcus 
pneumoniae, topoisomerase IV is the primary target of fluoroquinolones (Pan & 
Fisher, 1996; Ferrero et al., 1999). 
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A silent mutation was identified in the gyrA QRDR of fluoroquinolone resistant and 
susceptible C. coli isolates. C. coli NCTC 11283 and sample 20R possess a thymine at 
nucleotide 300, all other samples posses a cytosine at this position. Comparison with 
isolates from Zimstein et al (2000), C. coli ATCC 33559 and C. coli NCTC 11366 
show that these two isolates also possess a cytosine at this position. This difference at 
position 300 however does not result in a change at the amino acid level. 
Phenylalanine is the corresponding amino acid at codon 99. 
Secondary mutations have been identified in the pare genes of organisms with high-
level fluoroquinolone resistance (Vila et al. , 1996; Pan & Fisher, 1999; Bush & 
Goldschmidt, 2000). Whether secondary mutations in ParC are necessary for high-
level resistance in eampylobacter spp. has not been extensively investigated. In one 
report an Arg-139 to Gln mutation in ParC of C. jejuni was identified but it could not 
account for variation in susceptibilities to ciprofloxacin (Gibreel et al. , 1998). In this 
study numerous attempts to amplify the C. coli pare gene were carried out, without 
success. Thus, whether mutations in pare explain the increased resistance (~32 
µg/ml) of some of the C. coli isolates is unknown. There is also the possibility that 
additional mutations in gyrB, or parE may influence the level of resistance (Gibreel et 
al., 1998). 
Other mechanisms of resistance in C. coli cannot be ruled out: mutations in GyrA 
combined with altered outer membrane proteins or efflux mechanisms may result in a 
modest increase in MIC (Cambau & Gutmann, 1993). Charvalos et al. (1995) have 
suggested that an energy-dependent efflux system with a broad specificity is 
associated with multidrug resistance in C. jejuni. 
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CHAPTER4 
SUMMARY & GENERAL CONCLUSION 
Campylobacter coli and C. jejuni have been recognised as the leading causes of 
gastroenteritis worldwide (Tauxe, 1992). C. coli is the dominant species isolated from 
pigs while C. jejuni is commonly isolated from chickens. Fluoroquinolone resistance 
has been described in Campylobacter spp. (Piddock, 1995). In C. jejuni and C. coli, 
the incidence of fluoroquinolone resistance has increased steadily with reported rates 
as high as 88% in Spain, 84% in Thailand and 57% in Taiwan (Gallardo et al. , 1998; 
Hoge et al., 1998; Li et al., 1998; Saenz et al., 2000). Contaminated food particularly 
poultry is the usual source of infection (Tauxe, 1992) and the presence of 
fluoroquinolone resistant strains in the food chain has raised concerns. Firstly, it has 
been shown that patients infected with resistant C. jejuni have a longer duration of 
diarrhoea compared to patients with fluoroquinolone sensitive isolates (Smith et al., 
1999). The second concern relates to the treatment of human infections. Although 
most cases of campylobacteriosis are self-limiting and do not require antibiotic 
treatment, severe and prolonged infections often require treatment. Fluoroquinolones 
are the treatment of choice for adults and are also prescribed for prophylactic 
treatment against traveller' s diarrhoea (Taylor et al. , 1991 ; Nacharnkin, 1993; 
Piddock, 1995). Treatment failure in immunocompromised patients with 
campylobacteriosis is cause for concern in that it may increase Campylobacter-
associated deaths (Engberg et al., 2001). 
A total of 61 C. coli strains isolated from pigs were included in this study: 55 strains 
were obtained from pigs on farm A, while 6 strains were obtained from pigs on farm 
B, the source farm of pigs to farm A. Fifty-six percent (31/55) of strains from farm A 
were resistant to ciprofloxacin and nalidixic acid, while 67% ( 4/6) of strains from 
farm B were resistant to these antibiotics. Serotyping and flaA typing were carried out 
to study the epidemiology of the C. coli isolates. In addition, the molecular basis of 
the fluoroquinolone resistance was investigated. 
The serotypes of 62% (38/61) of isolates were obtained, the remainder were non-
typeable. Serotype 0 :24 (11/61) was the most frequent serotype identified, followed 
by 0:5 (7/61). All 0 :24 and 0:5 strains types were resistant to ciprofloxacin, 
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suggesting a relationship between these two serotypes and resistance, in the C. coli 
strains investigated. It is interesting to note that all 0:5 strains had ciprofloxacin MICs 
of ~32 µg/ml. Moreover, the flaA profile (profile 6) of the 0:24 strains was unique to 
this serotype. Thus, in this instance there was perfect correlation between serotype 
andflaA profile. Serotypes 0:48, 0:54 and 0:59 were identified in strains from both 
farms. RFLP analysis of the flaA gene revealed 13 distinct profiles in strains from 
farm A. Profile 1, including strains from farm A and farm B, was the commonest 
profile with 31 % (17 /55) of flaA typed strains in this profile. This profile was also 
observed in C. coli NCTC 11283. Two other profiles were common to both farms. 
These data suggest that some of the strains on the two farms are related. To be certain 
of the genetic identity of the isolates between farms it may be necessary to use an 
additional molecular typing scheme. 
Resistant and sensitive isolates were isolated from 15 pigs on farm A. flaA profiles 
were obtained for 12 pairs, of which 4 pairs each had the same flaA profile, 
suggesting selection of resistant mutants of a previously sensitive population. In this 
context, selective pressure exerted by the use of fluoroquinolones may have played a 
role. This is supported by data showing that since the introduction of fluoroquinolones 
in to veterinary medicine, the incidence of antibiotic resistant strains has increased in 
Europe (Piddock, 1995). 
No flaA product was amplified for 8% (5/61) of isolates. Investigation suggested a 
lack of complementarity between the primers and the target sequence at the 3' end. 
This data supports the findings of Harrington et al. (1997), who provided strong 
evidence of intragenomic recombination between the flaA and flaB genes of C. j ejuni. 
It is possible that similar recombination events have occurred in the flaA gene of the 
PCR refractory C. coli isolates, resulting in a lack of complementarity between 
primers and binding target. 
In C. jejuni and C. coli, it has been shown that a mutation of Thr-86 to Ile in the GyrA 
protein is associated with resistance to ciprofloxacin and nalidixic acid (Wang et al. , 
1993; Zimstein et al., 2000). Although other mutations in GyrA have been described 
these do not play an influential role in resistance (Wang et al., 1993). The mutation 
Thr-86 to Ile was identified in the GyrA protein of the resistant strains investigated in 
the study. 
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In addition to mutations in GyrA, Gibreel et al., (1998) identified a mutation in ParC. 
Secondary mutations in pare have been associated with high-level fluoroquinolone 
resistance in other organisms such as E. coli, S. pneumoniae and Enterobacter 
cloacae (Vila et al. , 1996; Deguchi et al., 1997; Pan & Fisher, 1999), although there 
was no convincing evidence that the mutation identified by Gibreel et al., (1998) was 
associated with fluoroquinolone resistance. Many attempts were made to PCR 
amplify the QRDR of pare without success. Whether additional mutations in pare 
could account for the varying ciprofloxacin MI Cs for C. coli is unknown. 
In conclusion, C. coli sensitive and resistant strains were isolated from pigs on two 
farms. RFLP flaA profiles suggested that although some of the isolates could be 
related, the majority of isolates were non-related. Serotype 24 and 5 strains were all 
resistant to ciprofloxacin and nalidixic acid, and profile 6 was unique to serotype 24. 
The profiles of paired resistant and sensitive isolates suggested that selection of 
resistant mutants from a previously sensitive population occurred, possibly by 
pressure exerted through use of fluoroquinolones. A mutation within the GyrA was 
associated with fluoroquinolone resistance. 
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APPENDIX A 
Buffers, Media and Solutions 
Ammonium Acetate (7.SM) 
Ammomnium acetate 
Distilled water 
Store at 4 °C. 
Ampicillin (100 mg/ml) 
Ampicillin 
Distilled water 
289g 
200 ml 
2g 
20 ml 
The solution is filter sterilized and stored in aliquots at -20 °C. For selective plates 
ampicillin is added to the media at a final concentration of 100 µg/ml. 
Chloroform-isoamylalcohol 
The chloroform is mixed at a ratio of24:1 with isoamylalcohol 
EDTA(O.SM) 
EDTA 
NaOH 
93.05 g 
10 g 
The ingredients are dissolved in 400 ml of water and autoclaved. 
Ethidium Bromide (EtBr) 
Ethidium Bromide 0.1 g 
Distilled Water 10 ml 
Gel Tracking Dye (6x) 
Bromophenol blue 
Sucrose 
EDTA (0.5 M, pH 8.0) 
Distilled water 
25 mg 
4g 
0.4 ml 
to 10 ml 
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Guanidium Thiocyanate Solution 
Guanidium Thiocyanate 60 g 
EDTA (0.5 M, pH 8.0) 20 ml 
Distilled water 20 ml 
The solution is heated to 65°C with mixing until dissolving. Solution is cooled and 5 
ml of 10% (w/v) N-Lauryl-Sarcosine Sodium salt is added and made upto 100 ml with 
distilled water. Solution is filtered through a 0.45 µm pore. 
IPTG (Isopropyl-P-D-thio-galactopyranoside) 
IPTG 2 g 
Distilled Water 8 ml 
The solution is mixed and made up to 10 ml and frozen in 1 ml aliquots at -20°C. For 
selective plates, 50 µl IPTG is added to 100 ml agar. 
Phenol 
Commercial crystallized 
phenol 
8-hydroxyquinoline 
NaOH (2 M) 
Distilled water 
Tris-HCl (1 M, pH 7.6) 
500 g 
0.6 g 
7.5 ml 
130 ml 
6ml 
The solution is liquefied at 40°C. The result is a solution of phenol in 10 mM Tris, 
pH7.6. 
Phosphate-Buffered Saline (PBS) 
NaCl 6.8 g 
3.5 g 
Made upto 1000 ml, pH adjusted to 7.0. 
Sodium Acetate (3M) 
Sodium acetate 
Distilled water 
204.05 g 
400 ml 
The pH is adjusted to 5.2 with glacial acetic acid and the volume made up to 500 ml. 
Stored at room temperature. 
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Sodium Hydroxide (10 N) 
Sodium hydroxide 40 g 
Distilled water 100 ml 
Solution I 
Tris-Cl (pH 8) 2.5 ml 
EDT A (0.5 M, pH 8) 10 ml 
Glucose (20% w/v) 5 ml 
Distilled water to 100 ml 
Solution II 
NaOH (ION) 2 ml 
SDS (20%wN) 5 ml 
Distilled water to 100 ml 
Solution III 
Potassium acetate (SM) 60 ml 
Glacial acetic acid 11.5 ml 
Distilled water to 100 ml 
Store at 4°C. 
SSC (lOX) 
C6H5Na307.2H20 0.15 M 
NaCl 1.5 M 
Tris-Acetate (TAE) Buffer (SOx) 
Tris 242 g 
Glacial acetic acid 
EDTA (0.5m, pH 8.0) 
57.1 g 
100 ml 
The ingredients are mixed in distilled water to a final volume of 1000 ml, autoclaved 
and stored at room temperature. 
To make IX solution, the buffer is diluted 50 fold. 
Tris-EDT A (TE) Buffer 
Tris 
EDTA 
The pH is adjusted to 7.6. 
lOmM 
lmM 
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X-gal (5-bromo-4-chloro-3-indoyl-P-D-galactoside) 
X-gal is dissolved in dimethyl sulfoxide (DMSO) at a concentration of 40 mg/ml. 
After the X-gal is dissolved, 1 volume of distilled water is added and the solution is 
stored at -20°C. 
For selective plates, 0.5 ml X-gal solution is added to 100 ml agar. 
2x YT Broth/ Agar 
Tryptone 
Yeast extract 
NaCl 
16 g 
10 g 
5g 
Made up to 1000 ml with distilled water and autoclaved 
For agar, 15 g is added. 
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APPENDIXB 
Molecular Weight Marker 
(kb) 
10.0 
8.0 
6.0 
5.0 
4.0 
3.0 
2.5 
2.0 
1.5 
1.0 
0.75 
0.50 
0.25 
Appendix Bl: 1kb DNA Ladder (Promega). 
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Appendix Cl: pUC19 
APPENDIXC 
Maps of Plasmids 
\ 
2~00 
pUC19 
2686 bps 
1000 
1~00 
I 
,Apa.B 1,179 
LNde 1.183 j :Nar I 
~ i.Bgl I 
' :! Pvu I 
·: t .. Pvull 
, 
500 
' 
87 
REFERENCES 
Adler, M., Luthy, H., Martinetti, L., Burnens, A. & Altwegg, M. (1991). 
Development of resistance to quinolones in five patients with campylobacteriosis 
treated with norfloxacin or ciprofloxacin. Eur J Clin Microbiol 10. 953-957. 
AIIos, B. M. (1997a). Campylobacter jejuni infection and the Guillain-Barre 
syndrome. Spec Med 14. 60-64. 
AIIos, B. M. (1997b ). Association between Campylobacter infection and Guillain-
Barre syndrome. J Infect Dis 176. 125-128. 
AIIos, B. M. & Blazer, M. J. (1995). Campylobacter jejuni and the expanding 
spectrum of related infections. Clin Infect Dis 20. 1092-1101. 
Alm, R., Guerry, P. & Trust, T. J. (1993a). Distribution and polymorphism of the 
flagellin gene from isolates of Campylobacter coli and Campylobacter jejuni. J 
Bacteriol 175. 3051-3057. 
Alm, R., Guerry, P. & Trust, T. J. (1993b). Significance of duplicated flagellin 
genes in Campylobacter. J Mo/ Biol 230. 359-363. 
Altekruse, S. F., Stern, N. J., Fields, P. I. & Swerdlow, D. L. (1999). 
Campylobacter jejuni-an emerging foodbome pathogen. Emerging Infectious 
Diseases 5. 28-35 . 
Altschul, S. F., Gish, W., Miller, W., Myers, E.W. & Lipman, J. (1990). Basic 
local alignment search tool. J Mol Biol 215. 403-410. 
Arbeit, R. D. (1995). Laboratory procedures for the epidemiological analysis of 
microorganisms. In Manual of Clinical Microbiology, 3rd edition, pp. 190-208. 
Edited by P.R. Murray. Washington D.C. : American Society for Microbiology. 
Asrat, D. A., Hathaway, A., Sjogren, E. S., EkwaII, E. & Kaijser, B. (1997). The 
serotype distribution of Campylobacter jejuni and Campylobacter coli isolated from 
patients with diarrhea and controls in Tikur Anbassa Hospital, Addis Ababa, Ethiopia. 
Epidemiol Infect 118. 91-95. 
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seiman, J. G., Smith, J. 
A. & Struhl, K. (1987). Current protocols in molecular biology. 
Ayling, R. D., Woodward, M. J., Evans, S. & NeweII, D. G. (1996). Restriction 
fragment length polymorphism of polymerase chain reaction products applied to the 
differentiation of poultry campylobacters for epidemiological investigations. Res Vet 
Sci 60. 168-172. 
88 
Birkenhead, D., Hawkey, P. M., Heritage J., Gascoyne-Binzi, D. M. & Kite, P. 
(1993). PCR for the detection and typing of Campylobacters. Lett Appl Microbiol 17. 
235-237. 
Black, R. E., Levine, M. M., Clements, M. L., Hughes, T. P. & Blaser, M. J. 
(1988). Experimental Campylobacter jejuni infection in humans. J Infect Dis. 157. 
472-479. 
Blaser, M. J. (1997). Epidemiologic and clinical features of Campylobacter jejuni 
infections. J Infect Dis 176 (Suppl. 2). S 103-S 105. 
Blaser, M. J., Allos, B. M. & Lang, D. (1997). Development of Guillain-Barre 
Syndrome following Campylobacter Infection. J Infect Dis 176. 91 . 
Blaser, M. J., Berkowitz, I. D., Laforce, M., Cravens, J., Reller, L. B. & Wang, 
W. I. (1979). Campylobacter enteritis: clinical and epidemiologic features. Ann 
Intern Med 91. 179-185. 
Blaser, M. J., Hopkins, A. & Vasil, M. L. (1984). Campylobacter enteritis. N Engl J 
Med 305. 1444-1452. 
Blaser, M. J., Moss, C. W. & Weaver, R. E. (1980). Cellular fatty acid composition 
of Campylobacter fetus . J Clin Microbiol 11. 448-451. 
Blaser, M. J. & Reller, L. B. (1981). Campylobacter enteritis. N Engl J Med 305. 
1444-1452. 
Blaser, M. J., Sazie, E. & Williams, L. P. Jr. (1987). The influence of immunity on 
raw milk-associated Campylobacter infection. JAMA 257. 43-46. 
Bourke, B., Sherman, P. M., Woodward, D., Lior, H. & Chan, V. L. (1996). 
Pulsed-field gel electrophoresis indicates genotypic heterogeneity among 
Campylobacter upsaliensis strains. FEMS Microbial Lett 142. 57-61. 
Bryan, J. P., Waters, C., Sheffield, J., Krieg, R. E., Perine, P. L. & Wagner, K. 
(1990). In vitro activities of tosufloxacin, temafloxacin and A-56620 against 
pathogens of diarhhea. Antimicrob Agents Chemother 34. 368-370. 
Burnens, A. P., Wagner, J., Lior, H., Nicolet, J. & Frey, J. (1995). Restriction 
fragment length polymorphism among the flagellar genes of the Lior heat-labile 
serogroup reference strains and field strains of Campylobacter jejuni and C. coli. 
Epidemiol Infect 114. 423-431. 
Bush, K. & Goldschmidt, R. (2000). Effectiveness of fluoroquinolones against 
gram-postive bacteria. Curr Opin Investig Drugs 1. 22-30. 
Butzler, J. P., Dekeyser, P., Detrain, M. & Dehaen, F. (1973). Related vibrio in 
stools. J Pediatr 82. 493-495. 
89 
Cambau, E. & Gutmann, L. (1993). Mechanisms of resistance to quinolones. 
Drugs 45. 15-23. 
Carter , A.M., Pacha, R.E., Clark, G.W. & Williams, E.A. (1987). Seasonal 
occurrence of Campylobacter spp. and their correlation with standard indicator 
bacteria. Appl Environ Microbial 53. 523-526. 
Charvalos, E., Tselentis, Y., Hamzehpour, M. M., Kohler, T. & Pechere, J.-C. 
(1995). Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. 
Antimicrob Agents Chemother 39. 2019-2022. 
Charvalos, E., Peteinaki, E., Spyridaki, I., Manetas, S. & Tselentis, Y. (1996). 
Detection of ciprofloxacin resistance mutations in Campylobacter jejuni gyrA by 
nonradioisotopic single-strand conformation polymorphism and direct DNA 
sequencing. J Clin Lab Anal 10.129-13 3. 
Dagert, M. & Ehrlich, S. D. (1979). Prolonged incubation in calcium chloride 
improves the competency of Escherichia coli cells. Gene 6. 23-28. 
Deguchi, T., Yasuda, M., Nakano, M., Ozeki, S., Kanematsu, E., Nishino, Y., 
Ishihara, S. & Kawada, Y. (1997). Detection of mutations in the gyrA and parC 
genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob 
Chemother 40. 543-549. 
De Melo, M. A. & Pechere, J. C. (1990). Identification of Campylobacter jejuni 
surface proteins that bind to eucaryotic cells in vitro. Infection and Immunity 58, 
1749-1756. 
Doyle, L. P. (1944). A vibrio associated with swine dysentery. Am J Vet Res 5. 3-5. 
Drlica, K. & Zhao, X. (1997). DNA gyrase, topoisomerase IV, and the 4-
quinolones. Microbial Mo! Biol Rev 61. 377-392. 
Dryden, M. S., Gabb, R. J. & Wright, S. K. (1996). Empirical treatment of severe 
acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 22. 
1019-1025. 
Duim, B., Wassennaar T. M., Rigter, A. & Wagenaar, J. A. (1999). High-
resolution genotyping of Campylobacter strains isolated from poultry and humans 
with AFLP fingerprinting. Appl Environ Microbial 65. 2369-2375. 
Du Pont, H. L., Ericsson, C. D., Robinson, A. & Johnson, P. C. (1987). Current 
problems in antimicrobial therapy for bacterial enteric infection. Am J Med 82. 324-
328. 
Edwards, U., Rogall, T., Blocker, H., Emde, M. & Bottger, E. (1989). Isolation 
and direct complete nucleotide determination of entire genes. Characterisation of gene 
coding for 16S ribosomal RNA. Nucl Acid Res 17. 7843-7853. 
90 
Ellis, P., Hyman, L. K., Ingram, R. J. & McCarthy, M. (1995). A placebo 
controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the 
community. J Antimicrob Chemother 36. 259-263. 
Endtz, H. P., Mouton, R. P., van der Reyden, T., Gijs, J. R., Biever, M. & van 
Klingeran, B. (1990). Flouroquinolone resistance in Campylobacter spp. isolated 
from human stools and poultry products. Lancet 335. 787. 
Endtz, H.P., Ruijs, G. J., van Klingeren, B., Jansen, W. H., van der Reyden, T. 
& Mouton, R. P. (1991). Quinolone resistance in Campylobacter isolated from man 
and poultry following the introduction of flouroquinolones in veterinary medicine. J 
Antimicrob Chemother 27. 199-208. 
Engberg, J., Aarestrup, F. M., Taylor, D. E., Gerner-Smidt, P. & Nachamkin, I. 
(2001). Quinolone and macrolide resistance in Carnpylobacter jejuni and C. coli: 
resistance mechanisms and trends in human isolates. Emerg Infect Dis 1. 24-34. 
Everett, M. J., Jin, Y-F. & Piddock, L. J. V. (1995). Molecular characterisation of 
gyrA-mediated flouroquinolone resistance in Campylobacter isolates from man and 
poultry [ abstract A224 7]. In Proceedings of the 191h International Congress of 
Chemotherapy. Montreal. 
Everett, M. J. & Piddock, L. J. V. (1997). Mechanisms of resistance to 
flouroquinolones. In Handbook of experimental pharmacology: quinolone 
antibacterials.Vol 7. pp 12. Edited by J. Kuhlmann, A. Dalhoff, H.-J. Zeiler. 
Heidelberg: Springer-Verlag. 
Fernie, D. S., Griffin, R. M. & Park, R. W. A. (1975). The possibiltity that 
Campylobacter (Vibrio) coli and Treponema hyodysenteriae are both involved in 
swine dysentery. Brit Vet J 131. 335-338. 
Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A. et 
al., (1999). Cloning and primary structure of Staphylococcus aureus DNA 
topoisomerase IV: a primary target of fluoroquinolones . Mo! Microbiol 13. 641-653. 
Fricker, C.R. & Park, R.W.A. (1988). Campylobacters in human, environmental 
and food samples from the Reading area with particular reference to toxin production 
and heat-stable serotype. J Appl Bacteriol 66. 477-490. 
Frost, J. A., Oza, A. N., Thwaites, R. T. & Rowe, B. 1998. Serotyping scheme for 
Campylobacter jejuni and Campylobacter coli based on direct agglutination of heat 
stable antigens. J Clin Microbiol 36. 335-339. 
Fujimoto, S., Allos, B. M., Misawa, N., Patton, C. M. & Blazer, M. J. (1997). 
Restriction fragment length polymorphism analysis and random amplified 
polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients 
with Guillain-Barre syndrome. J Infect Dis 176. 1105-1108. 
91 
Fujita, M., Fujimoto, S., Morooka, T. & Amako, K. (1995). Analysis of strains of 
Campylobacter fetus by pulsed-field gel electrophoresis. J Clin Microbial 33. 1676-
1678. 
Gallardo, F., Gascon, J., Ruiz, J., Corachan, M., de Anta, M. T. & Vila, J. (1998). 
Campylobacter jejuni as a cause of traveler's diarrhea: clinical features and 
antimicrobial susceptibility. J Travel Med 5. 23-26. 
Garrett, R, H. & Grisham, C, M. (1995). Recombinant DNA: cloning and creating 
chimeric genes. p272 In Biochemistry. Saunders College Publishing, Orlando. 
Gaunt, P. N. & Piddock, L. J. V. (1996). Ciprofloxacin resistant Campylobacter 
spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 37. 
747-757. 
Gebhart, C.J., Ward, G. E., Chang, K. & Kurtz, H. J. (1983). Campylobacter 
hyointestinalis (new species) isolated from swine with lesions of proliferative ileitis. 
Am. J Vet Res 44. 361-367. 
Gellert, M., Mizuuchi, K., O'Dea, M. H. & Nash, H. A. (1977). Nalidixic acid 
resistance: a second genetic character involved in DNA gyrase activity. Proc Natl 
Acad Sci USA 74. 4772-4776. 
Gibreel, A., Sjogren, E., Kaijser, B., Wretlind, B. & Skold, 0. (1998). Rapid 
emergence of high-level resistance to quinolones in Campylobacter jejuni associated 
with mutational changes in gyrA and parC. Antimicrob Agents Chemother 42. 3276-
3278. 
Gibson, J. R., Slater, E., Xerry, J., Tompkins, D.S. & Owen, R. J. (1998). Use of 
an amplified-fragment length polymorphism technique to fingerprint and differentiate 
isolates of Helicobacter pylori. J Clin Microbiol 36. 2580-2585. 
Goddard, E. A., Lastovica, A. J. & Argent, A. C. (1997). Campylobacter 0:41 
isolation in Guillain-Barre syndrome. Arch Dis Child 76. 526-528. 
Goossens, H., Giesendorf, B. A. J., Vandamme, P., Vlaes, L., Van den Borre, C., 
Koeken, A., Quint, W. G. V., Blomme, W., Hanicq, P., Koster, D. S., Hofstra, H., 
Butzler, J. P. & Van der Plas, J. (1995). Investigation of an outbreak of 
Campylobacter upsaliensis in day care centres in Brussels: analysis of relationships 
among isolates by phenotypic and genotypic typing methods. J Infect Dis 172. 1298-
1305. 
Goswitz, J. J., Willard, K. E., Fasching, C. E. & Peterson, L. R. (1992). Detection 
of gyr A gene mutations associated with ciprofloxacin resistance in methicillin-
resistant Staphylococcus aureus: analysis by polymerase chain reaction and 
automated direct DNA sequencing. Antimicrob Agents Chemother 36. 1166-1169. 
92 
Grant, C. C. R., Konkel, M. E., Cieplak, W. & Tompkins L. S. (1993). Role of 
flagella in adherance, internalization and translocation of Campylobacter jejuni in 
nonpolarized and polarized epithelial cell cultures. Infection & Immunity 61. 1764-
1771. 
Hallett, P. & Maxwell, A. (1991). Novel quinolone resistance mutations of the E. 
coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob 
Agents Chemother 35. 335-340. 
Harrington, C. S., Thomson-Carter, F. M. & Carter, P. E. (1997). Evidence for 
recombination in the flagellin locus of Campylobacter jejuni: implications for the 
flagellin gene typing scheme. Clin Microciol 35. 2386-2392. 
Harvey, S.M. (1980). Hippurate hydrolysis by Campylobacter fetus. J Clin 
Microbiol 11. 435-437. 
Hoge, C. W., Gambel, J. M., Srijan, A., Pitarangsi, C. & Echeverria, P. (1998). 
Trends in antibiotic resistance among diarrhoeal pathogens isolated in Thailand over 
15 years. Clin Infect Dis 26. 341-345. 
Ish-Horowicz, D. & Burke, J. F. (1981). Rapid and efficient cosmid cloning. 
Nucleic Acid Res 9. 2989-2998. 
Jacobs-Reitsma, W. F., Maas, H. M. E. & Jansen, W. H. (1995). Penner 
serotyping of Campylobacter isolates from poultry, with absorbed pooled antisera. J 
Appl Bacteriol 79. 286-291. 
Janssen, P., Coopman, R., Huys, G., Swings, J., Bleeker, M., Vos, P., Zabeau, M. 
& Kersters, K. (1996). Evaluation of the DNA fingerprinting method AFLP as a 
new tool in bacterial taxonomy. Microbiol 142. 1881-1889. 
Jones, P. H., Willis, A.T., Robinson, D. A., Skirrow, M. B. & Josephs, D. S. 
(1981 ). Campylobacter enteritis associated with the consumption of free school milk. 
J Hygiene 87. 155-162. 
Kampranis, S. C. & Maxwell, A. (1998). The DNA gyrase-quinolone complex. J 
Biol Chem 273. 22615-22626. 
Ketley, J. M. (1997). Pathogenesis of enteric infection by Campylobacter. 
Microbiol 143. 5-21. 
Kiehlbauch, J. A., Plikaytis, B. D., Swaminathan, B., Cameron, D. N. & 
Wachsmuth, I. K. (1991). Restriction fragment length polymorphisms in the 
ribosomal genes for species identification and subtyping of aerotolerant 
Campylobacter species. J Clin Microbiol 29. 1670-1676. 
King, E. 0. (1962). The laboratory recognition of Vibrio fetus and closely related 
Vibrio species isolated from cases of human vibriosis. Ann NY A cad Sci 98. 700-711. 
93 
King, V. & Clayton, C. L. (1991). Genomic investigation of phenotypic variation in 
Campylobacter jejuni flagellin. FEMS Microbial Lett 84. 107-112. 
Kist, M. (1985). The historical background of Campylobacter infection: new aspects. 
In Proceedings of the 3rd International Workshop on Campylobacter Infections; 
Otawa;1985 Jul 7-10. pp 23-27. Edited by A. D. Pearson. London. Public Health 
Laboratory Services. 
Koenraad, P. M. F. J., Jacobs-Reitsma, W. F., Van der Laan, T., Beumer, R.R. 
& Rombouts, F. M. (1995). Antibiotic susceptibility of Campylobacter isolates from 
sewage and poultry abattoir drain water. Epidemiol Infect 115. 475-483. 
Kokotovic, B. & On, S. L. W. (1999). High-resolution genomic fingerprinting of 
Campylobacter jejuni and Campylobacter coli by analysis of amplified fragment 
length polymorphisms. FEMS Microbial Lett 173. 77-84. 
Krieg, N.R. (1984). Aerobic/microaerophilic, motile, helical/vibroid Gram-negative 
bacteria. In Bergey 's manual of systematic bacteriology, Vol. 1. pp71-72 
Kureishi, A., Diver, J.M., Beckthold, B., Schollaardt, T. & Bryan, L. E. (1994). 
Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene 
from strain PAO 1 and quinolone-resistant clinical isolates. Antimicrob Agents 
Chemother 38. 1944-1952. 
Kuroki, S., Saida, T., Nukina, M., Haruta, T., Yoshioka, M., Kobayashi, Y. & 
Nakanishi, H. (1993). Campylobacter jejuni strains from patients with Guillain-
Barre syndrome belong mostly to Penner serogroup 19 and contain B-N-
acetylglucosamine residues. Ann Neural 33. 243-247. 
Kuschner, R. A., Trofa, A. F., Thomas, R. J., Hoge, C. W., Pitarangsi, C. & 
Amato, C. et al. (1995). Use of azithromycin for the treatment of Campylobacter 
enteritis in travellers to Thailand, an area where ciprofloxacin resistance is prevalent. 
Clin Infect Dis 21. 536-541 . 
Laanbroek, H.J., Kingma, W., & Veldkamp, H. (1977). Isolation of an aspartate-
fermenting, free-living Campylobacter species. FEMS Microbial Lett 1. 99-102. 
Edited by N.R. Krieg & J.G. Holt. Baltimore: The Williams and Wilkins Co. 
Lastovica, A. J., Goddard, E. A. & Argent, A. C. (1997). Guillain-Barre syndrome 
in South Africa associated with Campylobacter jejuni 0:41 strains. J Infect Dis 
176(Suppl. 2). 139-143. 
Lastovica, A. J. & Skirrow, M. B. (2000). Clinical significance of Campylobacter 
and related species other that Campylobacter jejuni and C. coli. In Campylobacter, 2nd 
Edition, pp 89-120. Edited by I. Nachamkin & M. J. Blaser. Washington DC: 
American Society for Microbiology. 
94 
Le Roux, E. & Lastovica, A. J. (1998). The Cape Town protocol: how to isolate the 
most Campylobacters for your dollar, pound, franc, yen, etc. In Campylobacters, 
Helicobacters, and Related Organisms, pp 30-33. Edited by A. J. Lastovica, D. G. 
Newell & E. E. Lastovica. Institute of Child Health. 
Levy, A. J. (1946). A gastroenteritis outbreak probably due to a bovine strain of 
Vibrio. Yale J Biol Med 18. 243-258. 
Li, C. C., Chiu, C.H., Wu, J. L., Huang, Y. C. & Lin, T. Y. (1998). Antimicrobial 
susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J 
Infect Dis 30. 39-42. 
Lin, J.-J. & Kuo, J. (1995). AFLP: a novel PCR-based assay for plant and bacterial 
DNA fingerprinting. Focus 17. 52-56. 
Lior, H., Woodward, D. L., Edgar, J. A., Laroche, L. J. & Gill, P. (1982). 
Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile 
antigenic factors. J Clin Microbial 15, 761-768. 
Lorenz, E., Lastovica, A. J. & Owen, R. J. (1998). Subtypes of Campylobacter 
jejuni Penner serotypes 9, 38, and 63 from human infections, animals and water by 
pulsed field gel electrophoresis and flagellin gene analysis. Lett Appl Microbial 26. 
179-182. 
Madden, R. H., Moran, L. & Scates, P. (1996). Sub-typing of animal and human 
Campylobacter spp. using RAPD. Lett Appl Microbial 23. 167-170. 
Maniatis , T., E. F. Fritsch & J. Sambrook. (1982). Gel Electrophoresis. In 
Molecular Cloning a Laboratory Manual, 1st edition, pp 149-185. New York: Cold 
Spring Harbour Laboratory Press. 
Marshall, S. M., Melito, P. L., Woodward, D. L., Johnson, W. M., Rodgers, F. G. 
& Mulvey, M. R. (1999). Rapid identification of Campylobacter, Arcobacter, and 
Helicobacter isolates by PCR-Restriction Fragment Length Polymorphism analysis of 
the 16S rRNA gene. J Clin Microbial 37. 4158-4160. 
Matsheka, M. I. (2000). Molecular identification and typing of Campylobacter 
concisus. Unpublished Post-Doctoral Thesis. University of Cape Town, South Africa. 
24. 
Maxwell, A. (1992). The molecular basis of quinolone action. J Antimicrob 
Chemother 30. 409-414. 
McFadyean, J. & Stockman, S. (1913). Report of the departmental committee 
appointed by the board of agriculture and fisheries to inquire into epizootic abortion. 
Part III: Abortion in sheep. London: HMSO. 
McKay D., Fletcher, J., Cooper, P. & Thomson-Carter, F. M. (2001). Comparison 
of two methods for serotyping Campylobacter spp. J Clin Microbial 39. 1917-1921 . 
95 
Meinersmann, R. J., Helstel, L. 0., Fields, P. I. & Hiett, K. L. (1997). 
Discrimination of Campylobacter jejuni isolates by fla gene sequencing. J Clin 
Microbial 35. 2810-2814. 
Meunier, J. -R. & Grimont, P. A. D. (1993). Factors affecting reproducibility of 
random amplified polymorphic DNA fingerprinting. Res Microbial 144. 373-379. 
Mills, S. D., Kurjanczyk, L. A., Shames, B., Hennessy, J. N. & Penner, J. L. 
(1991). Antigenic shifts in serotype determinants of Campylobacter coli are 
accompanied by changes in the chromosomal DNA restriction endonuclease digestion 
pattern. J Med Microbial 35. 168-173. 
Mohran, Z.S., Guerry, P., Lior, H., Murphy, J. R., El-Gendy, A. M., Mikhail, M. 
M. & Oyofo, B. A. (1996). Restriction fragment length polymorphism of flagellin 
genes of Campylobacter jejuni and/or C. coli isolated from Egypt. J Clin Microbial 
34. 1216-1219. 
Moutinho-Fragoso, G., Johnson, W. M., Wang, G., Correia da Silva, R. & 
Cabrita, J. (1998). A different toxic effect in tissue culture caused by 
Campylobacter porin? In Campylobacter, Helicobacter & related organisms, pp. 
312-316. Edited by A. J. Lastovica, D. G. Newell & E.E. Lastovica. Cape Town: 
Institute of Child Health. 
Nachamkin, I. (1993). Campylobacter infections. Curr Opin Infect Dis 6. 72-76. 
Nachamkin, I., Bohachick, K. & Patton, C. M. (1993). Flagellin gene typing of 
Campylobacter jejuni by restriction fragment length polymorphism analysis. J Clin 
Microbial 31. 1531-1536. 
Nachamkin, I., Ung, H. & Patton, C. M. (1996). Analysis of HL and O serotypes of 
Campylobacter strains by the flagellin gene typing system. J Clin Microbial 34. 277-
281. 
Nachamkin, I., Mishu Allos, B. & Ho, T. (1998). Campylobacter species and 
Guillain-Barre syndrome. Clin Microbial Rev 11. 555-567. 
National Advisory Committee on Microbiological Criteria for Foods. (1993). 
Campylobacter jejuni/coli. J Food Protect 57. 1101-1121. 
National Committee for Clinical Laboratory Standards. (1998a). Methods for 
dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. 
National Committee for Clinical Laboratory Standards 
National Committee for Clinical Laboratory Standards. (1998b) Performance 
standards for antimicrobial disc susceptibility test. National Committee for Clinical 
Laboratory Standards 
96 
Newell, D. G. & On, S. L. W. (1998). Speciation and subtyping of Campylobacters, 
Helicobacters and related organisms: a survey of current applications. In 
Campylobacter, Helicobacter & Related Organisms, pp. 213-215. Edited by A. J. 
Lastovica, D. G. Newell & E.E. Lastovica. Institute of Child Health. 
Newell, D. G., Frost, J. A., Duim, B., Wagenaar, J. A., Madden, R. H., van der 
Plas, J. & On, S. L. W. (2000). New development in the subtyping of 
Campylobacter species. In Campylobacter, 2nd Edition, pp 27-44. Edited by I. 
Nachamkin & M. J. Blaser. Washington DC: American Society for Microbiology. 
Nicol, C. & Wright, J. (1998). Campylobacter typing in New Zealand. In 
Campylobacter, Helicobacter & related organisms, pp. 61-64. Edited by A. J. 
Lastovica, D. G. Newell & E.E. Lastovica. Cape Town: Institute of Child Health. 
Nielsen, E. M., Engberg, J. & Madsen, M. (1997). Distribution of serotypes of 
Campylobacter jejuni anq C. coli from Danish patients, poultry, cattle and swine. 
FEMS Immunol Med Microbial 19. 47-56. 
Nishimura, M., Nukina, M., Yuan, J. M., Shen, B. Q., Ma, J. J., Ohta, M., Saida, 
T. & Uchiyama, T. (1996). PCR-based restriction fragment length polymorphism 
(RFLP) analysis and serotyping of Campylobacter jejuni isolates from diarrheic 
patients in China and Japan. FEMS Microbial Lett 142. 133-138. 
Nishimura, M., Nukina, M., Kuroki, S., Obayashi, H., Ohata, M., Ma, J. J., 
Saida, T. & Uchiyama, T. (1997). Characterisation of Campylobacter jejuni isolates 
from patients with Guillain- Barre syndrome. J Neur Science 153. 91-99. 
Nuijten, P. J.M., Van Asten, F. J. A. M., Gaastra, W. & Van Der Zeijst, A. M. 
(1990). Structural and functional analysis of two Campylobacter jejuni flagellin 
genes. J Biolog Chem 265. 17798-17804. 
Occhialini, A., Sonnet, V., Hua, J., Camou, C., Guesdon, J. L. & Megraud, F. 
(1996). Identification of strains of Campylobacter jejuni and Campylobacter coli by 
PCR and correlation with phenotypic characteristics. In Campylobacters, 
Helicobacters, and Related Organisms, pp 217-219. Edited by D. G. Newell, J.M. 
Ketley, & R. A. Feldman. New York, N.Y. Plenum Press. 
On, S. L. W. (2000). Personal communication. 
On, S. L. W. (1996). Identification methods for Campylobacter, Helicobacter, and 
related organisms. Clin Microbial Rev 9. 405-422. 
On, S.L.W., Holmes, B. & Sackin, M. (1996). A probability matrix for the 
identification of campylobacters, helicobacters, and allied taxa. J Appl. Bacterial 81. 
425-432. 
Owen, R. J., Desai, M. & Garcia, S. (1993a). Molecular typing of thermotolerant 
species of Campylobacter with ribosomal RNA gene patterns. Res Microbial 144. 
709-720. 
97 
Owen, R. J., Fayos, A., Hernandez, J. & Lastovica, A. (1993b). PCR-based 
restriction fragment length polymorphism analysis of DNA sequence diversity of 
flagellin genes of Campylobacter jejuni and allied species. Mo! Cell Probes 7. 471-
480. 
Owen, R. J., Sutherland, K., Fitzgerald, C., Gibson, J., Borman, P. & Stanley, J. 
(1995). Molecular subtyping scheme for serotypes HSI and HS4 of Campylobacter 
jejuni. J Clin Microbial 33. 872-877. 
Pan, X. S. & Fisher, L. M. (1996). Cloning and characterisation of the parC and 
pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in 
flouroquinolone resistance. J Bacterial 178. 4060-4069. 
Pan, X. S. & Fisher, L. M. (1999). Streptococcus pneumoniae DNA gyrase and 
topoisomerase IV: overexpression, purification, and differential inhibition by 
fluoroquinolones. Antimicrob Agents Chemother 43. 1129-1136. 
Penner, J. L. & Hennessey, N. (1980). Passive haemagglutination technique for 
serotyping Campylobacter fetus subsp.jejuni on the basis of heat-stable antigens. J 
Clin Microbial 12. 732-737. 
Piddock, L. J. V. (1995). Quinolone resistance and Campylobacter spp.. J 
Antimicrob Chemother 36. 891-898. 
Pitcher, P. G. N., Saunders, N. A. & Owen, R. J. (1989). Rapid extraction of 
bacterial genomic DNA with Guanidium thiocyanate. Lett Appl Microbial 8. 151-156. 
Prescott, J. F. & Baggott, J. D. (1993). Antimicrobial therapy in veterinary 
medicine. 2nd ed. Ames (IA): Iowa State University Press. 
Prescott, L. M., Harley, J. P. & Klein, D. A. (1996). The bacteria: gram-negative 
bacteria of general, medical, or industrial importance. In Microbiology, Third 
Edition, pp 415-437. Chicago: Wm. C. Brown Publishers. 
Rolfs, A., Schuller, I., Finckh, U. & Weber-Rolfs, I. (1992). In PCR: Clinical 
diagnosis and research. p 34, Springer-Verlag, Berlin Heidelberg. 
Rollins, D.M. & Colwell, R.R. (1986). Viable but nonculturable stage of 
Campylobacter jejuni and its role in survival in the natural aquatic environment. Appl 
Env Microbial 52. 531-538. 
Rosef, 0. (1981 ). Isolation of Campylobacter fetus subsp. jejuni from the gallbladder 
of normal slaughter pigs, using an enrichment procedure. Acta Vet Scand 22. 149-151. 
Ruiz, J., Goni, P., Marco, F., et al. (1998). Increased resistance to q~inolones in 
Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-
resistant clinical isolates. Microbial Immunol 42. 223-226. 
98 
Saenz, Y., Zarazaga, M., Lantero, M., Gastanares, M. J., Baquero, F. & Torres, 
C. (2000). Antibiotic resistance in Campylobacter strains isolated from animals, 
foods, and humans, in Spain in 1997-1998. Antimicrob Agent Chemother 44. 267-271. 
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, T., 
Mullis, K. B. & Erhlich, H. A. (1988). Primer-directed enzymatic amplification of 
DNA with a thermostable DNA polymerase. Science 239. 487-491. 
Salama, S. M., Tabor, H., Richter, M. & Taylor, D. E. (1992). Pulsed-field gel 
electrophoresis for epidemiologic ·studies of Campylobacter hyointestinalis isolates. J 
Clin Microbiol 30. 1982-1984. 
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Gel Electrophoresis. In 
Molecular cloning: A Laboratory Manual, 2nd edition, pp. 150-185. New York: Cold 
Spring Harbour Laboratory Press. 
Santesteban, E., Gibson, J. & Owen, R. J. (1996). Flagellin gene profiling of 
Campylobacter jejuni heat-stable serotype 1 and 4 complex. Res Microbiol 147. 641 -
649. 
Segreti, J., Gootz, T. D., Goodman, L. J., Parkhurst, G. W., Quinn, J.P., Martin, 
B. A. & Trenholme, G. M. (1992). High-level quinolone resistance in clinical 
isolates of Campylobacter jejuni. J Infect Dis 165. 667-670. 
Sharples, G. T. & Lloyd, R. G. (1990). A novel repeated DNA sequence located in 
the intergenic regions of bacterial chromosomes. Nucl Acid Res 18. 6503-6508. 
Sjogren, E., Lindblom, G. B. & Kaijser, B. (1997). Norfloxacin resistance in 
Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. J 
Antimicrob Chemother 40. 257-261. 
Skirrow, M. B. (1977). Campylobacter enteritis: A "new" disease. Br. Med. J 2. 9-
11. 
Skirrow, M. B. (1994). Disease due to Campylobacter, Helicobacter and related 
bacteria. J Comp Path 111. 113-149. 
Skirrow, M. B. & Benjamin, J. (1980). Differentiation of enteropathogenic 
Campylobacter. J Clin Path 33. 1122. 
Skirrow, M. B., Fidoe, R. G. & Jones, D. M. (1981 ). An outbreak of presumptive 
food-borne campylobacter enteritis. J Infect 3. 234-236. 
Skirrow, M. B. & Blaser, M. J. (1992). Clinical and epidemiological considerations. 
In Campylobacter jejuni: Current Status and Future Trends, pp 3-8. Edited by I. 
Nachamkin, M. J. Blaser & L. S. Tompkins. Washington DC: American Society for 
Microbiology. 
99 
Skirrow, M. B. & Blaser, M. J. (2000). Clinical aspects of Campylobacter 
infection. In Campylobacter, 2nd Edition, pp 69-88. Edited by I. Nachamkin & M. J. 
Blaser. Washington DC: American Society for Microbiology. 
Slater, E. & Owen, R. J. (1998). Subtyping of Campylobacter jejuni Penner heat-
stable (HS) serotype 11 isolates from human infection. J Med Microbial 41. 353-357. 
Smibert, R.M. (1978). Genus Campylobacter. Ann Rev Micro biol 32. 673-709. 
Smith, K., Besser, J. M., Hedberg, C. W., Leano, F. T., Bender, J. B. & 
Wicklund, J. H. et al. (1999) Quinolone-resistant Campylobacter jejuni infections in 
Minnesota, 1992-1998. N Engl J Med 340. 1525-1532. 
Sreedharan, S., Peterson, L. R. & Fisher, L. M. (1991 ). Ciprofloxacin resistance in 
in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in 
the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. 
AntimicrobAgents Chemother. 35. 2151-2154. 
Stanley, J., Linton, D., Sutherland, K., Jones, C. & Owen, R. J. (1995). High-
resolution genotyping of Campylobacter coli identifies clones of epidemiologic and 
evolutionary significance. J Infect Dis 172. 1130-1134. 
Steele, T. W. & Owen, R. J. (1988). Campylobacter jejuni subspecies doylei (subsp. 
nov.), a subspecies of nitrate-negative Campylobacters isolated from human clinical 
specimens. Int J Syst Bacterial 38. 316-318. 
Stern, N.J., Hernandez, M.O., Blankenship, L., Deibel, K.E., Doores, S., Doyle, 
M.P., Ng, H., Pierson, M.D., Sofos, J.N., Sveum, W.H. & Westhoff, D.C. (1985). 
Prevalence and distribution of Campylobacter jejuni and Campylobacter coli in retail 
meats. J Food Protect 48. 595-599. 
Sugino, A., Peebles, C. L., Kreuzer, K. N. & Cozzarelli, N. R. (1977). Mechanism 
of action of nalidixic acid: purification of Escherichia coli nalA gene product and its 
relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci 
USA 74. 4767-4771. 
Svedhem, A. & Kaijser, B. (1981 ). Isolation of Campylobacter jejuni from domestic 
animals and pets: probable origin of human infection. J Infect 3. 37-40. 
Taylor, D. E. (1992). In Campylobacter jejuni: current status and future trends, pp 
74-86. Edited by I. Nachamkin, M. J. Blaser & L. S. Tompkins. Washington D.C: 
American Society for Microbiology. 
Taylor, D. E. & Chau, S. -S. (1997). Cloning and nucleotide sequence of the gyrA 
gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of 
ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob Agents Chemother 
41. 665-671. 
100 
Taylor, D. E., Ng, L. K. & Lior, H. (1985). Susceptibility of Campylobacter species 
to nalidixic acid, enoxacin, and other DNA gyrase inhibitors. Antimicrob Agents 
Chemother 28. 708-710. 
Taylor, D. N., Sanchez, J. L., Candler, W., Thornton, S., McQueen, C. & 
Escheverria, P. (1991). Treatment of traveller's diarrhea: ciprofloxacin plus 
loperamide compared with ciprofloxacin alone. Ann Intern Med 114. 731-734. 
Tauxe, R. V. (1992). Epidemiology of Campylobacter jejuni infections in the United 
States and other industrial nations. In Campylobacter jejuni: current status andfuture 
trends, pp 9-19. Edited by I. Nachamkin, M. J. Blaser & L. S. Tompkins. Washington 
D.C: American Society for Microbiology. 
Tee, W., Mayall, B., Lucas, C. R., Rayner, R., Pearson, S. & Dwyer, B. (1992). 
Use of ribosomal RNA gene restriction patterns to investigate two outbreaks of 
Campylobacter enteritis in Melbourne, Australia. J Med Microbiol 37. 385-388. 
U.S. Food & Drug Administration. (2000). Campylobacter jejuni. 
http://vm.cfsan.fda.gov/-mow/ 
Vandamme, P. (2000). Taxonomy of the family Campylobacteraceae. In 
Campylobacter, 2 nd Edition, pp 3-26. Edited by I. Nachamkin & M. J. Blaser. 
Washington DC: American Society for Microbiology. 
Vandamme, P., Falsen, E., Rossau, R., Hoste, B., Segers, P., Tygat, R. & De Ley, 
J. (1991). Revision of Campylobacter, Helicobacter and Wolinella taxonomy: 
emendation of generic descriptions and proposal of Arcobacter gen. nov. Int J Syst 
Bacteriol 41. 88-103. 
Vandamme, P. & Goosens, H. (1992). Taxonomy of Campylobacter, Arcobacter 
and Helicobacter: a review. Zbl Bakt 276. 447-472. 
Velazquez, J.B., Jimenez, A., Chomon, B. & Villa, T. G. (1995). Incidence and 
transmission of antibiotic resistance in Campylobacter jejuni and Campylobacter coli. 
J Antimicrob Chemother 35. 173-178. 
Vila, J., Ruiz, J., Marco, F., Barcelo, A., Goiii, P., Giralt, E. & Jimenez De Anta, 
T. (1994). Association between double mutation in gyrA gene of ciprofloxacin-
resistant clinical isolates of Escherichia coli and MI Cs. Antimicrob Agents Chemother 
38. 2477-2479. 
Vila, J., Ruiz, J., Goiii, P., Marcos, A. & Jimenez De Anta, T. (1995). Mutation in 
the gyrA gene of quinolone-resistant isolates of Acinetobacter baumannii. 
Antimicrob Agents Chemother 39. 1201-1203. 
Vila, J., Ruiz, J., Goiii, P. & Jimenez De Anta, M. T. (1996). Detection of 
mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. 
Antimicrob Agents Chemother 40. 491-493 . 
101 
Vos, P., Hogers, R., Bleeker, M., Reijans, M., van der Lee, T., Hornes, M., 
Frijters, A., Pot, J., Peleman, J., Kuiper, M. & Zabeau, M. (1995). AFLP: a new 
technique for DNA fingerprinting. Nucleic Acids Res 23. 4407-4414. 
Wang, Y., Huang, W. M. & Taylor, D. E. (1993). Cloning and nucleotide sequence 
of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance 
mutations. Antimicrob Agents Chemother 37. 457-463 . 
Wassenaar, T. M., Fry, B. N. & van der Zeijst, B. A. M. (1995). Variation of the 
flagellin gene locus of Campylobacter jejuni by recombination and horizontal gene 
transfer. Microbial 141. 95-101. 
Wassenaar, T. M. & Newell, D. G. (2000). Genotyping of Campylobacter spp. App 
Environ Microbial 66. 1-9. 
Weijtens, M. J., Reinders, R. D., Urlings, H.A. & Van der Plas, J. (1999). 
Campylobacter infections in fattening pigs ; excretion pattern and genetic diversity. J 
Appld Microbial 86. 63-70. 
Welsh, J. & McClelland, M. (1990). Finger-printing genomes using PCR with 
arbitrary primers. Nucleic Acids Res 18. 7213-7218. 
Williams, J. G. K., Kubelik, A. R., Livak, K. L., Rafalski, J. A. & Tingey, S. V. 
(1990). DNA polymorphisms amplified by arbitrary primers are useful as genetic 
markers. Nucleic Acid Res 18. 6531-6535. 
Willmott, C. J. R. & Maxwell, A. (1993). A single point mutation in the DNA 
gyrase A protein greatly reduces binding of flouroquinolones to the gyrase-DNA 
complex. Antimicrob Agents Chemother 37. 126-127. 
Wolfson, J. S. & Hooper, D. C. (1989). Flouroquinolone antimicrobial agents. Clin 
Microbial Rev 2. 378-424. 
Yan, W., Chang, N. & Taylor, D. E. (1991). Pulsed-field gel electrophoresis of 
Campylobacter jejuni and Campylobacter coli genomic DNA and its epidemiologic 
application. J Infect Dis 163. 1068-1072. 
Yanagisawa, A. (1980). Large outbreak of campylobacter enteritis among school 
children. Lancet ii. 153. 
Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990). Quinolone 
resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. 
Antimicrob Agents Chemother 37. 457-463. 
Yuki, N., Takahashi, M., Tagawa, Y., Kashiwase, K., Tadokoro, K. & Saito, K. 
(1997). Association of Campylobacter jejuni serotype and antiganglioside antibody 
in Guillain-Barre syndrome and Fisher' s syndrome. Ann Neural 42. 28-33. 
102 
Zirnstein, G. W., Li, Y., Swaminathan, B. & Angulo, F. (1999). Ciprofloxacin 
resistance in Campylobacter jejuni isolates: detection of gyrA resistance mutations by 
MAMA PCR and DNA sequence analysis. J Clin Microbial 31. 3276-3280. 
Zirnstein, G., Helsel, L., Li, Y., Swaminathan, B. & Besser, J. (2000). 
Characterization of gyrA mutations associated with flouroquinolone resistance in 
Campylobacter coli by DNA sequence analysis and MAMA PCR. FEMS Microbial 
Lett 190. 1-7. 
103 
